World Journal of Biology Pharmacy and Health Sciences
eISSN: 2582-5542
Cross Ref DOI: 10.30574/wjbphs
Journal homepage: https://wjbphs.com/

(REVIEW ARTICLE)

Check for updates

Nanobiotechnology-driven innovations for tackling antimicrobial resistance

Oluwaseyi Ajibola Fagbemi [1, *], Matthew Essuah [2], Darlignton Chukwuma Ugwu [3], Adeola Badrat Ajibola [4], Sarah Oluwaseun Julius [5], Ikemefuna Nnamdi Onyeyili [6] and Damilola Samuel Ojo-omoniyi [7]

[1] *Department of Human Anatomy, College of Medicine, Federal University Lokoja, Kogi State, Nigeria.*
[2] *Department of Allied Health Sciences, Kwame Nkrumah University of Science and Technology, Ghana.*
[3] *Department of Health Emergency Preparedness and Response, Nigeria Centre for Disease Control and Prevention.*
[4] *Department of Animal Nutrition and Biotechnology, Ladoke Akintola University of Technology, Oyo, Nigeria.*
[5] *Department of Microbiology, University of Ibadan, Nigeria.*
[6] *Department of treatment care and support, AIDS Healthcare Foundation Lokoja, Nigeria.*
[7] *Department of Pharmaceutical Chemistry, University of Ibadan, Nigeria.*

World Journal of Biology Pharmacy and Health Sciences, 2025, 21(02), 300-328

Publication history: Received on 14 December 2024; revised on 07 February 2025; accepted on 10 February 2025

Article DOI: https://doi.org/10.30574/wjbphs.2025.21.2.0093

Abstract

Antimicrobial resistance (AMR) is an escalating global health crisis, challenging the efficacy of conventional antibiotics and necessitating novel approaches to infection management. This review explores the transformative role of nanobiotechnology in addressing AMR by leveraging the unique properties of nanomaterials for diagnostics, therapeutics, and vaccine development. Nanoparticles exhibit diverse mechanisms of action, including biofilm penetration, targeted drug delivery, and reactive oxygen species (ROS) generation, providing a multi-faceted approach to combating resistant pathogens. Innovations such as metallic nanoparticles, nanozymes, and lipid-based nanocarriers demonstrate significant potential in disrupting resistance mechanisms, enhancing the efficacy of existing antimicrobials, and reducing the likelihood of resistance development. Additionally, this review examines the integration of advanced methodologies like CRISPR-based gene editing and artificial intelligence (AI) to optimize nanoparticle design and function. Emerging applications in resource-limited settings highlight the scalability and accessibility of nanobiotechnological solutions, addressing healthcare disparities in regions disproportionately affected by AMR. However, challenges such as nanoparticle toxicity, environmental impact, and regulatory barriers underscore the need for interdisciplinary collaboration to ensure the safe and ethical deployment of these technologies. By synthesizing current advancements and addressing the barriers to clinical translation, this review underscores the transformative potential of nanobiotechnology in revolutionizing AMR management and safeguarding global health. Continued innovation and multidisciplinary cooperation will be critical to harnessing the full potential of nanobiotechnology in the fight against resistant infections.

Keywords: Nanobiotechnology; Antimicrobial resistance; Nanoparticles; Drug delivery; CRISPR; nanozymes; Biofilm disruption; Metagenomics; Vaccine development

1. Introduction

Antimicrobial resistance (AMR) represents a formidable challenge to global public health, characterized by the diminishing efficacy of standard treatments against a spectrum of infections. It is one of the gravest threats to global public health, with far-reaching implications for human health, animal well-being, and economic stability. The World Health Organization (WHO) has identified AMR as one of the top ten threats to global health, and has repeatedly emphasized the urgency of addressing this issue, warning that AMR could reverse decades of progress in medicine and usher in a "post-antibiotic era" where minor infections and routine surgeries become life-threatening. The emergence

* Corresponding author: Oluwaseyi Ajibola Fagbemi; Email: seyikizz@gmail.com

of multidrug-resistant pathogens, fueled by the misuse and overuse of antibiotics in clinical and agricultural settings, has compounded the crisis. According to Chakraborty et al. [1], global estimates attribute 4.95 million deaths annually to drug-resistant bacterial infections, with 1.27 million directly caused by AMR. This growing threat demands innovative and interdisciplinary solutions that extend beyond traditional antimicrobial strategies.

Efforts to develop new antibiotics have been hindered by scientific, economic, and logistical challenges. The pipeline for novel antimicrobials has dwindled, with only a few agents reaching late-stage clinical trials in recent decades. Furthermore, the adaptability of pathogens, often through genetic mutations and horizontal gene transfer, allows them to rapidly circumvent even newly developed drugs. This dynamic is exacerbated by the ability of certain bacteria, such as *Staphylococcus aureus* and *Klebsiella pneumoniae*, to form biofilms that act as protective barriers, rendering them resistant to conventional treatments [2].

In this context, nanobiotechnology has emerged as a transformative frontier with the potential to overcome these limitations. By leveraging the unique physicochemical properties of nanoparticles, such as their high surface area-to-volume ratio and tunable functionalities, researchers have developed innovative approaches for combating AMR. Nanoparticles offer multiple mechanisms of action, including direct microbial destruction via oxidative stress, disruption of bacterial membranes, and enhanced delivery of existing antibiotics to infection sites. These properties make them particularly effective against biofilm-associated infections and intracellular pathogens, which are notoriously difficult to treat using standard antibiotics [3]. This interdisciplinary field leverages the unique physicochemical properties of nanoscale materials to develop novel therapeutic and diagnostic tools. Nanoparticles, due to their high surface area-to-volume ratio and tunable surface functionalities, can interact with microbial cells in ways that circumvent traditional resistance mechanisms. For instance, metallic nanoparticles such as silver and gold have demonstrated intrinsic antimicrobial properties, including the ability to disrupt bacterial cell membranes and generate reactive oxygen species, leading to cell death. Additionally, nanocarriers can enhance the delivery and efficacy of existing antibiotics by facilitating targeted delivery, improving solubility, and enabling controlled release. These advancements suggest that nanobiotechnology could play a pivotal role in developing next-generation antimicrobials capable of overcoming the challenges posed by resistant pathogens.



Figure 1 Recent advancements in nanobiotechnology (nanobiotics) in tackling AMR. Reproduced from Ref [1] with permission

Recent advancements in nanotechnology have also paved the way for novel applications in diagnostics, therapeutics, and vaccine development (See Figure 1). Metallic nanoparticles, such as silver (AgNPs) and zinc oxide (ZnO), have

demonstrated broad-spectrum antimicrobial activity, while liposome-based nanocarriers have shown promise in delivering drugs with improved efficacy and reduced toxicity. Additionally, the development of nanozymes—catalytic nanoparticles that mimic natural enzymes—offers exciting opportunities for biofilm disruption and reactive oxygen species generation to combat resistant pathogens [4].

Despite these promising developments, the field of nanobiotechnology faces several challenges that must be addressed before its full potential can be realized. These include concerns over nanoparticle toxicity, environmental impact, scalability, and regulatory approval. Furthermore, the translation of nanobiotechnology from laboratory settings to clinical applications requires robust preclinical and clinical studies to establish safety, efficacy, and cost-effectiveness. As highlighted by Chakraborty et al. [1], interdisciplinary collaboration and public engagement are essential to overcoming these barriers and ensuring the successful integration of nanobiotechnology into global healthcare systems.

This review aims to provide a comprehensive analysis of nanobiotechnology's role in combating AMR, exploring its mechanisms of action, recent advancements, and potential applications. It will also critically evaluate the challenges and limitations associated with this field and propose strategies for addressing these obstacles. By synthesizing insights from current research, this paper seeks to underscore the transformative potential of nanobiotechnology in addressing one of the most pressing public health challenges of our time.

As the global health community grapples with the escalating threat of AMR, nanobiotechnology offers a beacon of hope. Its innovative approaches have the potential to circumvent existing resistance mechanisms and restore the efficacy of antimicrobial therapies. However, realizing this potential requires addressing existing challenges through rigorous research and collaboration across disciplines [5]. The subsequent sections of this review will delve deeper into the specific applications, benefits, and obstacles associated with nanobiotechnology in the context of AMR, providing a roadmap for future research and development in this promising field.

2. Nanobiotechnology Solutions for AMR



Figure 2 A Schematic diagram illustrating Nanoparticle Mechanisms in Combating AMR. Reproduced from Ref [7] with permission

The field of nanobiotechnology has gained significant attention for its potential to revolutionize antimicrobial resistance (AMR) management. Unlike traditional antibiotics, which often fail against resistant pathogens due to biofilm formation, genetic mutations, or efflux pump mechanisms, nanobiotechnology offers a versatile platform to combat these challenges [1,6]. Nanoparticles possess unique physicochemical properties, including high surface area-to-volume ratios, tunable functionalities, and the ability to interact with bacterial systems at a molecular level. These features

enable nanoparticles to disrupt biofilms, enhance drug delivery, and target resistant pathogens through mechanisms that reduce the likelihood of further resistance development.

According to Chakraborty et al. [1], the multifunctionality of nanomaterials allows for applications beyond direct antimicrobial action, including use as drug carriers and diagnostic tools. For example, metallic nanoparticles such as silver and zinc oxide have demonstrated inherent bactericidal properties, while polymeric nanocarriers improve drug stability and reduce toxicity. This section delves into the various nanobiotechnology-based approaches to combat AMR, focusing on nanoparticle-mediated drug delivery, metallic nanoparticles, and emerging technologies like nanozymes (see Figure 2).

2.1. Nanoparticle-Based Drug Delivery Systems

Nanoparticle-based drug delivery systems have emerged as a transformative approach in combating antimicrobial resistance (AMR). By harnessing the unique properties of nanoparticles, researchers have developed advanced drug delivery platforms capable of overcoming the limitations of conventional antibiotic therapies [7]. These systems enhance the efficacy of antimicrobial agents through targeted delivery, controlled release, and improved solubility, while also addressing key challenges like biofilm penetration and intracellular infections.

Nanocarriers offer distinct advantages over conventional antibiotics, especially when dealing with resistant pathogens. They enable targeted delivery, minimize off-target effects, and enhance the therapeutic index of antibiotics. This is achieved through encapsulation, functionalization, or conjugation of antibiotics with nanomaterials, which improves their efficacy while reducing toxicity. To illustrate these advantages, Table 1 provides a comparison of nanocarrier-based antibiotic delivery systems and their traditional counterparts in terms of their mechanisms and results.

Table 1 Comparative Efficacy of Nanocarriers and Traditional Antibiotics

Antibiotic/Nanocarrier	Pathogen	Resistance Overcome	Delivery Mechanism	Results
Liposomal Vancomycin	Methicillin-Resistant Staphylococcus aureus (MRSA)	Methicillin resistance	Encapsulation of vancomycin in liposomes	Minimum inhibitory concentration (MIC) reduced by 50% compared to free vancomycin. [7]
Cephradine-Loaded Silver and Gold Nanoparticles	Escherichia coli and Staphylococcus aureus	Beta-lactam resistance	Antibiotic conjugation with metal nanoparticles	Enhanced antibacterial effect with lower MIC compared to cephradine alone. [6]
Ampicillin-Conjugated Gold Nanoparticles	Pseudomonas aeruginosa, Enterobacter aerogenes, and Methicillin-Resistant Staphylococcus aureus (MRSA)	Multidrug resistance	Functionalization of gold nanoparticles with ampicillin	Effective bactericidal activity against multiple antibiotic-resistant strains. [5]
Silver Nanoparticles Combined with Amoxicillin, Penicillin, or Gentamicin	Various bacterial strains	Multiple antibiotic resistances	Synergistic combination of silver nanoparticles with antibiotics	Improved activity of antibiotics, reducing the MIC required for bacterial inhibition. [5]
Lipid Nanoparticle-Encapsulated Antibiotics	Various bacterial strains	General antibiotic resistance	Encapsulation of antibiotics in lipid-based nanoparticles	Reduced collateral damage to gut microbiota and enhanced delivery to target sites. [5]

2.1.1. Mechanisms: Targeted Delivery, Controlled Release, and Enhanced Solubility

Nanoparticles offer unparalleled advantages in drug delivery by enabling the precise targeting of resistant pathogens, thereby minimizing off-target effects and enhancing therapeutic outcomes. Targeted delivery mechanisms rely on surface modifications of nanoparticles with ligands, such as antibodies, peptides, or small molecules, that specifically bind to receptors on bacterial cells. According to Nazli et al. [8], these modifications facilitate the selective delivery of antibiotics to infection sites, bypassing systemic circulation and reducing the risk of toxicity. For instance, nanoparticles functionalized with mannose have been shown to bind effectively to *Escherichia coli* via lectin receptors, achieving higher localized drug concentrations compared to non-targeted systems. Controlled release is another critical

mechanism enabled by nanoparticle-based systems. Polymeric nanoparticles, such as those made from poly(lactic-co-glycolic acid) (PLGA), are designed to release encapsulated drugs in a sustained manner, maintaining therapeutic concentrations over extended periods. Zou et al. [2] highlighted that controlled-release nanoparticles could reduce dosing frequency and improve patient compliance, particularly for chronic infections. In one study by Hua et al [9], ciprofloxacin-loaded PLGA nanoparticles demonstrated a prolonged drug release profile, maintaining antimicrobial activity against *Pseudomonas aeruginosa* for up to 72 hours [9].

Enhanced solubility of hydrophobic antibiotics is a significant advantage offered by nanoparticle-based systems. Many potent antimicrobial agents suffer from poor aqueous solubility, limiting their bioavailability and therapeutic efficacy. Liposomes, which are lipid bilayer vesicles, encapsulate hydrophobic drugs within their lipid phase, dramatically improving solubility. Himanshu et al. [3] reported that amphotericin B-loaded liposomes effectively treated fungal infections, overcoming the solubility challenges associated with free amphotericin B.

2.1.2. Applications: Case Studies of Nanoparticles Delivering Antibiotics to Resistant Pathogens

The application of nanoparticle-based drug delivery systems has shown tremendous potential in treating infections caused by multidrug-resistant (MDR) bacteria. A notable example is the use of silver nanoparticles (AgNPs) as drug carriers. AgNPs not only exhibit intrinsic antimicrobial properties but also enhance the delivery of conventional antibiotics. Chakraborty et al. [1] demonstrated that amoxicillin-loaded AgNPs exhibited synergistic activity against *Staphylococcus aureus*, significantly reducing bacterial growth compared to amoxicillin alone.

Liposomes have also been extensively studied as nanocarriers for antibiotic delivery. Zou et al. [2] described the efficacy of vancomycin-loaded liposomes in targeting *Methicillin-resistant Staphylococcus aureus* (MRSA) biofilms. The liposomal formulation improved drug penetration into the biofilm matrix, resulting in a 90% reduction in bacterial viability. This finding underscores the potential of liposomes to overcome the protective barriers that hinder conventional antibiotic therapies. Polymeric nanoparticles, particularly those based on PLGA and chitosan, have gained attention for their versatility and biocompatibility. Himanshu et al. [3] highlighted a study where chitosan nanoparticles loaded with gentamicin exhibited enhanced antimicrobial activity against *Klebsiella pneumoniae* biofilms. The nanoparticles facilitated sustained drug release and improved penetration into biofilm-embedded bacterial cells, achieving superior therapeutic outcomes compared to free gentamicin.

Biofilm Penetration: Overcoming Biofilm Barriers with Nanosystems

Biofilms are structured communities of bacteria encased in an extracellular polymeric substance (EPS) matrix, which serves as a protective barrier against antibiotics and immune responses. Overcoming biofilm-related resistance is one of the most significant challenges in AMR management, and nanoparticle-based systems offer promising solutions. The small size of nanoparticles allows them to penetrate the dense EPS matrix, delivering antimicrobial agents directly to the embedded bacteria [10-12].

According to Olatunji et al. [4], metallic nanoparticles, such as zinc oxide and gold nanoparticles, exhibit biofilm-disrupting properties by generating reactive oxygen species (ROS) that degrade the EPS matrix. In one study, zinc oxide nanoparticles demonstrated the ability to penetrate *Pseudomonas aeruginosa* biofilms, reducing bacterial viability by over 80%. These findings highlight the potential of metallic nanoparticles to address biofilm-associated infections that are resistant to conventional therapies.

Nanoparticle-mediated drug delivery also enhances the efficacy of existing antibiotics against biofilms. Zou et al. (2023) reported that ciprofloxacin-loaded polymeric nanoparticles effectively disrupted *Staphylococcus epidermidis* biofilms, achieving complete eradication within 48 hours. This result underscores the synergistic potential of combining nanotechnology with traditional antibiotics. Furthermore, nanozymes, which mimic natural enzymatic activity, have been shown to degrade biofilm matrices through catalytic mechanisms. Chakraborty et al. [1] described the use of cerium oxide nanozymes to disrupt biofilms formed by *Enterococcus faecalis*, demonstrating their potential as a novel anti-biofilm strategy.

2.2. Metallic Nanoparticles with Intrinsic Antimicrobial Properties

Metallic nanoparticles (MNPs) have emerged as a pivotal innovation in the fight against antimicrobial resistance (AMR), offering potent, multifaceted mechanisms of action against resistant pathogens. Unlike traditional antibiotics that target specific cellular processes, metallic nanoparticles leverage their nanoscale dimensions and surface functionalities to disrupt bacterial systems in diverse ways [13]. These nanoparticles—comprising silver (Ag), gold (Au), zinc oxide (ZnO), and others—exhibit inherent antimicrobial properties that make them particularly effective against multidrug-resistant

bacteria, including biofilm-associated pathogens. By targeting bacterial membranes, inducing oxidative stress, and releasing toxic ions, metallic nanoparticles circumvent many of the mechanisms that confer resistance to conventional antibiotics [13,14]. To provide a comprehensive understanding, Table 2 summarizes the primary mechanisms of action of various nanoparticles and their efficacy against specific resistant pathogens.

Table 2 Mechanisms of Action of Nanoparticles Against Resistant Pathogens

Nanoparticle Type	Mechanism of Action	Targeted Pathogen	Literature Reference	Efficacy Data
Silver Nanoparticles (AgNPs)	Induction of oxidative stress through reactive oxygen species (ROS) generation, leading to DNA/RNA damage and disruption of membrane integrity.	Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa	Antibacterial properties of nanoparticles [14]	Demonstrated significant bactericidal activity at low concentrations.
Gold Nanoparticles (AuNPs)	Disruption of bacterial cell membranes and interference with protein synthesis.	Salmonella typhimurium, Enterococcus faecalis	Antibiotic properties of nanoparticles [14]	Showed enhanced antibacterial effects when functionalized with antibiotics.
Zinc Oxide Nanoparticles (ZnO NPs)	Generation of ROS causing oxidative stress, leading to lipid peroxidation and membrane damage.	Staphylococcus aureus, Escherichia coli	Antibiotic properties of nanoparticles [14]	Exhibited strong antibacterial activity with minimal cytotoxicity.
Copper Nanoparticles (CuNPs)	Release of copper ions disrupting enzymatic processes and inducing oxidative stress.	Listeria monocytogenes, Salmonella enterica	Antibiotic properties of nanoparticles [14]	Effective at low concentrations against various pathogens.
Graphene Oxide (GO) Nanosheets	Physical disruption of cell membranes and extraction of phospholipids, leading to cell lysis.	Escherichia coli, Staphylococcus aureus	Antibiotic properties of nanoparticles [14]	Achieved high antibacterial efficiency through membrane disruption.
Carbon Nanotubes (CNTs)	Penetration and disruption of bacterial cell walls, leading to leakage of intracellular contents.	Bacillus subtilis, Klebsiella pneumoniae	Antibiotic properties of nanoparticles [14]	Demonstrated potent antibacterial activity with potential for functionalization.
Mesoporous Silica Nanoparticles (MSNs) with Silver	Sustained release of silver ions causing prolonged antimicrobial effects.	Mycobacterium tuberculosis	Mesoporous silica nanoparticles containing silver as novel antimycobacterial agents against Mycobacterium tuberculosis [13]	Showed significant reduction in bacterial viability in vitro.

2.2.1. Mechanisms: Membrane Disruption, Oxidative Stress, and Ion Release

The antimicrobial activity of metallic nanoparticles is largely attributed to their ability to disrupt bacterial membranes, induce oxidative stress, and release antimicrobial ions. Membrane disruption is a primary mode of action, wherein nanoparticles interact with the bacterial cell membrane, leading to structural damage and leakage of intracellular contents. This interaction is facilitated by the electrostatic attraction between the positively charged nanoparticles and the negatively charged bacterial membranes, as demonstrated by Modi et al. [15]. In one study, silver nanoparticles

disrupted the membrane integrity of *Escherichia coli* and *Staphylococcus aureus*, resulting in significant bacterial death within hours of exposure.

Oxidative stress induction is another critical mechanism by which metallic nanoparticles exert their antimicrobial effects. These nanoparticles catalyze the production of reactive oxygen species (ROS), such as hydrogen peroxide, hydroxyl radicals, and superoxide anions. ROS generation leads to oxidative damage of cellular components, including proteins, lipids, and DNA, ultimately causing cell death. Olatunji et al. [4] reported that zinc oxide nanoparticles exhibited superior ROS generation capabilities, effectively killing *Pseudomonas aeruginosa* and *Klebsiella pneumoniae* biofilm-associated bacteria.

Ion release further amplifies the antimicrobial properties of metallic nanoparticles. Upon interaction with bacterial cells or exposure to specific physiological conditions, these nanoparticles release metal ions that interfere with critical cellular functions. Silver ions (Ag^+), for example, are known to bind to thiol groups in proteins and enzymes, disrupting metabolic pathways and DNA replication. This multi-targeted approach reduces the likelihood of resistance development, as bacteria would need to undergo multiple simultaneous mutations to counteract these effects. According to Zou et al. [2], ion release from gold nanoparticles was instrumental in eradicating methicillin-resistant *Staphylococcus aureus* (MRSA) in vitro.

2.2.2. Examples: Silver, Gold, and Zinc Oxide Nanoparticles in Combating Resistant Bacteria

Silver nanoparticles (AgNPs) are among the most extensively studied metallic nanoparticles for their antimicrobial properties. Their efficacy against a wide range of resistant bacteria, including MRSA and *Escherichia coli*, has been well-documented [16]. Himanshu et al. [3] highlighted a study where AgNPs reduced MRSA biofilm formation by over 80% within 24 hours. This was achieved through a combination of membrane disruption, ROS generation, and Ag^+ ion release, which collectively led to bacterial eradication. Moreover, silver nanoparticles have been incorporated into wound dressings and coatings for medical devices, where they provide long-lasting antimicrobial protection.

Gold nanoparticles (AuNPs) are another versatile class of metallic nanoparticles with significant potential in combating AMR. While less inherently toxic than silver, AuNPs can be functionalized with antibiotics or other therapeutic agents to enhance their antimicrobial activity. Wang et al. [17] reported that gold nanoparticles functionalized with vancomycin demonstrated enhanced activity against vancomycin-resistant *Enterococci* (VRE), achieving up to a 90% reduction in bacterial viability. The ability to tailor the surface chemistry of AuNPs allows for targeted delivery and synergistic effects, making them an attractive option for resistant infections.

Zinc oxide nanoparticles (ZnO NPs) are particularly effective against biofilm-associated infections. Their high ROS generation capacity and ability to penetrate biofilms have made them a focus of recent research. Chakraborty et al. (2022) described a study in which ZnO NPs eradicated *Pseudomonas aeruginosa* biofilms by inducing oxidative stress and disrupting the EPS matrix. This dual-action mechanism resulted in complete biofilm clearance within 48 hours, demonstrating the potential of ZnO NPs to address one of the most challenging aspects of AMR.

2.2.3. Synergistic Applications: Combining Metallic Nanoparticles with Existing Antibiotics

One of the most promising aspects of metallic nanoparticles is their ability to work synergistically with existing antibiotics, enhancing their efficacy and overcoming resistance mechanisms. This synergism is achieved through multiple pathways, including improved drug delivery, enhanced penetration into biofilms, and complementary modes of action. Zou et al. [2] reported that combining silver nanoparticles with ciprofloxacin significantly reduced the minimum inhibitory concentration (MIC) of the antibiotic against *Klebsiella pneumoniae*. The nanoparticles disrupted the bacterial membrane, allowing higher intracellular concentrations of ciprofloxacin, which then inhibited DNA replication.

Gold nanoparticles have also been shown to enhance the activity of antibiotics. In one study by Hagbani et al [18], vancomycin-functionalized gold nanoparticles exhibited superior efficacy against vancomycin-resistant *Staphylococcus aureus* (VRSA) compared to vancomycin alone. This effect was attributed to the ability of the gold nanoparticles to bypass resistance mechanisms, such as efflux pumps, that would otherwise reduce the drug's efficacy.

Zinc oxide nanoparticles have demonstrated synergistic effects when combined with tetracycline. Abdelghafar et al. [19] highlighted a study where ZnO NPs enhanced the penetration of tetracycline into *E. coli* biofilms, achieving a 70% reduction in biofilm mass. This combination therapy not only improved antibiotic efficacy but also reduced the likelihood of resistance development by targeting bacteria through multiple pathways.

2.3. Nanozymes and Novel Catalytic Nanomaterials

Nanozymes, a groundbreaking class of nanomaterials with enzyme-like catalytic properties, have garnered significant attention for their potential to combat antimicrobial resistance (AMR). These synthetic enzyme mimetics are engineered to perform catalytic functions analogous to natural enzymes, such as oxidases, peroxidases, and catalases [20]. Unlike biological enzymes, nanozymes are structurally robust, exhibit remarkable stability under diverse environmental conditions, and can be precisely tailored for specific applications. Their ability to degrade biofilms and generate reactive oxygen species (ROS) positions them as a powerful tool in addressing multidrug-resistant bacterial infections, particularly those involving biofilm-associated pathogens [21,22]. The role of nanotechnology in addressing antimicrobial resistance (AMR) extends beyond therapeutic delivery to advanced diagnostics. Innovative diagnostic platforms utilizing nanomaterials have proven transformative in identifying resistant pathogens and tailoring treatment strategies. These advancements are particularly critical in early detection and management of AMR. Table 3 provides an overview of key nanotechnology-driven diagnostic innovations, their mechanisms, and their contributions to AMR detection.

Table 3 Advances in Nanotechnology-Based Diagnostics for Antimicrobial Resistance

Diagnostic Technology	Nanotechnology Utilized	Target Pathogen(s)	Detection Method	Advantages
Rapid Sepsis Test	Magnetic nanoparticles	Various bacterial pathogens	Pathogen identification and antibiotic susceptibility testing	Reduces diagnosis time to 13 hours, enabling quicker targeted treatment
Automated Optical System for Antimicrobial Susceptibility Testing (AST)	Optical nanomaterials	Staphylococcus aureus	Deep learning analysis of bacterial growth	Provides early AST results, minimizing incubation time and eliminating human errors
Nanomechanical Sensor for Antibiotic-Mucopeptide Binding	Cantilever arrays	Staphylococcus aureus	Detection of vancomycin binding to bacterial cell wall precursors	Offers label-free detection with high sensitivity at clinically relevant concentrations
Nanoscale Devices for Real-Time Monitoring	Various nanomaterials	Multiple bacterial species	Real-time monitoring of bacterial populations	Allows early detection of resistance development
Nanotechnology-Based Detection Platforms	Various nanomaterials	Multiple pathogens	Rapid and sensitive pathogen identification	Enhances diagnostic speed and sensitivity

2.3.1. Nanozymes as Enzyme Mimetics for Biofilm Degradation and ROS Generation

Nanozymes are nanomaterials that mimic enzymatic activities by catalyzing biochemical reactions, effectively breaking down biofilm matrices and targeting bacterial systems. Their catalytic activity stems from their nanoscale architecture, which provides a high surface area-to-volume ratio and facilitates interactions with bacterial systems at the molecular level. According to Chakraborty et al. [1], nanozymes are particularly effective in generating ROS, such as hydroxyl radicals and superoxide ions, which are highly reactive and capable of damaging bacterial membranes, proteins, and nucleic acids. This catalytic ROS generation disrupts bacterial homeostasis and ultimately leads to cell death.

Biofilms represent one of the most challenging aspects of AMR. These structured communities of bacteria, encased in an extracellular polymeric substance (EPS) matrix, act as a physical and biochemical barrier, protecting bacterial cells from antibiotics and the host immune system. Nanozymes have demonstrated the ability to degrade these biofilm matrices through catalytic mechanisms. For instance, cerium oxide nanoparticles (CeO_2 nanozymes) exhibit peroxidase-like activity, breaking down hydrogen peroxide into ROS that attack the EPS matrix. Himanshu et al. [3] highlighted that these nanozymes effectively penetrated biofilms formed by *Pseudomonas aeruginosa* and *Staphylococcus aureus*, achieving significant reductions in biofilm biomass and bacterial viability.

Nanozymes also outperform natural enzymes in terms of stability and resilience. While natural enzymes are often susceptible to denaturation under extreme pH, temperature, or salinity conditions, nanozymes maintain their catalytic functionality across a wide range of environmental conditions [23]. This robustness makes them particularly suited for treating infections in diverse physiological and environmental contexts.

2.3.2. Nanozymes Targeting Multidrug-Resistant Gram-Negative Bacteria

Gram-negative bacteria, characterized by their complex outer membrane and intrinsic resistance mechanisms, pose a significant challenge in AMR management. Nanozymes have demonstrated remarkable efficacy in targeting these pathogens. According to Zou et al. [2], iron oxide nanozymes (Fe_3O_4) have shown peroxidase-like activity that enhances the penetration of antibiotics into the protective layers of Gram-negative bacteria, such as *Escherichia coli* and *Klebsiella pneumoniae*. These nanozymes generate ROS in situ, degrading the outer membrane and facilitating the entry of antimicrobial agents.

Gold-based nanozymes (AuNZs) have also emerged as potent tools in combating Gram-negative bacteria. Their catalytic activity, combined with their biocompatibility, makes them ideal candidates for treating multidrug-resistant infections. Ma et al. [24] described the use of AuNZs functionalized with antimicrobial peptides to target *Acinetobacter baumannii*. The nanozymes not only generated ROS but also disrupted bacterial membranes, achieving complete eradication of the pathogen in in vitro models.

Another promising example is manganese oxide nanozymes (MnO_2), which exhibit dual catalytic activities as oxidases and catalases. These nanozymes have been shown to degrade EPS matrices and generate ROS, effectively combating biofilms formed by *Pseudomonas aeruginosa*. Chakraborty et al. [1] reported that MnO_2 nanozymes reduced biofilm mass by over 75% within 48 hours, demonstrating their potential as a novel therapeutic strategy for biofilm-associated infections.

The multifunctionality of nanozymes extends to their ability to act synergistically with existing antibiotics. Zou et al. [3] highlighted a study where cerium oxide nanozymes were combined with ciprofloxacin to treat biofilm-associated infections caused by *Staphylococcus epidermidis*. The nanozymes degraded the biofilm matrix, allowing ciprofloxacin to penetrate deeper into the biofilm and achieve higher bacterial eradication rates.

2.4. Vaccines and Immunotherapeutics

The escalating threat of antimicrobial resistance (AMR) necessitates innovative strategies beyond traditional antibiotic development. Nanobiotechnology offers promising avenues, particularly in enhancing vaccine efficacy and developing novel immunotherapeutics. By leveraging nanoscale materials, researchers aim to potentiate immune responses against resistant pathogens, thereby reducing reliance on antibiotics and mitigating the spread of resistance [25,26].

2.4.1. Nano-Based Adjuvants: Enhancing Immune Responses Against Resistant Pathogens

Adjuvants are critical components of vaccines, designed to enhance the body's immune response to an antigen. Traditional adjuvants, such as aluminum salts, have limitations, including suboptimal induction of cellular immunity and potential side effects. Nanotechnology introduces a new generation of adjuvants with improved efficacy and safety profiles [27,28].

Nanoparticle-based adjuvants can be engineered to possess unique physicochemical properties that modulate the immune system more effectively. For instance, clay nanoparticles, or nanoclays, have demonstrated strong adjuvant activity, leading to immune responses significantly more potent than those elicited by conventional adjuvants like alum. Studies have shown that layered double hydroxides and hectorite nanoparticles can enhance both humoral and cellular immunity, making them promising candidates for vaccine formulations against resistant pathogens [29-31].

Furthermore, the size, shape, and surface charge of nanoparticles can be tailored to optimize antigen delivery and presentation. Nanoparticles can protect antigens from degradation, facilitate targeted delivery to antigen-presenting cells, and promote sustained antigen release, leading to prolonged immune stimulation. This precision in design allows for the induction of specific immune responses, such as Th1 or Th2 pathways, which are crucial in combating different types of infections, including those caused by resistant bacteria [32].

In addition to synthetic nanoparticles, natural nanomaterials are being explored as adjuvants. Saponin-based nanoparticles, such as Matrix-M, have been utilized in various vaccine candidates, including the Novavax COVID-19 vaccine. Matrix-M is composed of nanoparticles derived from saponins extracted from the Quillaja saponaria tree,

combined with cholesterol and phospholipids. This adjuvant has been shown to enhance both antibody and T-cell responses, offering cross-protection against multiple strains of pathogens [33].

The application of nanoparticle-based adjuvants extends to combating AMR by enhancing the efficacy of vaccines against resistant bacterial strains. By inducing robust and specific immune responses, these adjuvants can reduce the incidence of infections caused by resistant pathogens, thereby decreasing the need for antibiotic use and slowing the development of resistance.

2.4.2. Case Studies: Lipid Nanoparticles in mRNA Vaccines and Their Implications for Bacterial AMR

The success of lipid nanoparticle (LNP)-encapsulated mRNA vaccines in the context of viral infections, notably COVID-19, has spurred interest in their application against bacterial pathogens, including those exhibiting antimicrobial resistance [34,35]. LNPs serve as delivery vehicles that protect mRNA from degradation and facilitate its uptake by host cells, where it is translated into antigenic proteins that elicit immune responses.

A pioneering example is the development of an mRNA-LNP vaccine targeting *Yersinia pestis*, the bacterium responsible for plague. Researchers engineered mRNA encoding the F1 capsular antigen of *Y. pestis*, encapsulated within LNPs. This vaccine elicited significant cellular and humoral immune responses in animal models, demonstrating the potential of mRNA-LNP platforms in bacterial vaccine development [36].

The implications of such technologies for AMR are profound. Vaccines that effectively prevent infections by resistant bacteria can reduce the reliance on antibiotics, thereby diminishing the selective pressure that drives the emergence of resistance [37,38]. Moreover, mRNA vaccine platforms offer rapid development and scalability, which are crucial in responding to emerging resistant bacterial threats.

Another study by Knudson et al. [39] explored the use of LNP-encapsulated mRNA vaccines to induce protective memory CD8 T cells against viral diseases. While this research focused on viral pathogens, the findings suggest that similar strategies could be employed to generate robust cellular immunity against intracellular bacterial pathogens, including those resistant to multiple drugs.

The versatility of LNPs extends beyond mRNA delivery. They can be adapted to carry various nucleic acids, proteins, or small molecules, making them suitable for a range of immunotherapeutic applications. For instance, LNPs have been utilized to deliver CRISPR-Cas13a systems for the targeted degradation of viral RNA, a strategy that could be adapted for bacterial pathogens [40].

In essence, nanobiotechnology, through the development of nanoparticle-based adjuvants and LNP-encapsulated mRNA vaccines, offers innovative solutions to combat AMR. By enhancing immune responses and providing platforms for rapid vaccine development, these technologies hold the promise of reducing the burden of resistant infections and curbing the spread of antimicrobial resistance. As research advances, the integration of nanotechnology into vaccine and immunotherapeutic design will play a pivotal role in addressing the global challenge of AMR.

2.5. Synergistic Effects of Nanoparticles and Antibiotics

The combination of nanoparticles and conventional antibiotics has emerged as a promising strategy to combat antimicrobial resistance (AMR). Nanoparticles enhance the efficacy of antibiotics by facilitating their delivery, disrupting bacterial membranes, and overcoming resistance mechanisms such as efflux pumps and biofilm barriers. This synergistic approach significantly reduces the minimum inhibitory concentration (MIC) of antibiotics, making them more effective against resistant pathogens (see Figure 3).



Figure 3 Synergistic activity of nanoparticles loaded with antibiotics. Reproduced from Ref [22] with permission

Silver nanoparticles (AgNPs), for instance, have demonstrated potent synergistic effects when combined with antibiotics such as kanamycin, amikacin, and vancomycin, particularly against multidrug-resistant strains of *Escherichia coli* and *Staphylococcus aureus*. The mechanism involves increased cell membrane permeability and disruption, which enhance the antibiotics' intracellular activity. Zinc oxide nanoparticles (ZnO-NPs) have also been shown to inhibit biofilm formation and improve the penetration of antibiotics into bacterial cells, further amplifying their antibacterial effects.

Table 4 summarizes key findings on the synergistic effects of various nanoparticles and antibiotics, highlighting their potential to revolutionize AMR management by improving antibiotic efficacy and reducing resistance development.

Table 4 Synergistic Effects of Nanoparticles and Existing Antibiotics

Nanoparticle Type	Antibiotic	Target Pathogen	Mechanism of Synergy	Efficacy Increase (% MIC Reduction)
Silver Nanoparticles (AgNPs)	Kanamycin	Escherichia coli	AgNPs disrupt bacterial cell membranes, enhancing kanamycin uptake. [41]	MIC reduced from 4 µg/mL to 1 µg/mL for kanamycin (75% reduction); AgNPs MIC reduced from 128 µg/mL to 16 µg/mL (87.5% reduction). [41]
Silver Nanoparticles (AgNPs)	Amikacin	Multidrug-resistant clinical strains	AgNPs increase cell membrane permeability, facilitating amikacin entry [42].	MIC reduced by 2- to 32-fold, depending on the strain. [42]

Silver Nanoparticles (AgNPs)	Ampicillin	Staphylococcus aureus and Enterobacter cloacae	AgNPs cause structural damage to bacterial membranes, improving ampicillin efficacy [42].	MIC reduced by 1-fold for *S. aureus* and 4-fold for *E. cloacae* [42].
Silver Nanoparticles (AgNPs)	Colistin	Escherichia coli	AgNPs enhance colistin's binding to bacterial membranes [41].	Synergistic effect with ΣFIC value of 0.5 [41].
Silver Nanoparticles (AgNPs)	Rifampicin	Escherichia coli	AgNPs facilitate rifampicin penetration into bacterial cells [41].	Synergistic effect with ΣFIC value of 0.3 [41].
Silver Nanoparticles (AgNPs)	Vancomycin	Escherichia coli	AgNPs disrupt outer membrane, allowing vancomycin access [41].	MIC reduced from 128 μg/mL to 8 μg/mL for AgNPs (93.75% reduction); ΣFIC = 0.1 [41].
Zinc Oxide Nanoparticles (ZnO-NPs)	Various antibiotics	Staphylococcus aureus and Escherichia coli	ZnO-NPs inhibit biofilm formation, enhancing antibiotic effectiveness [19].	MIC values for tested antibiotics were reduced when combined with ZnO-NPs, giving FIC values ≤ 0.5, indicating a synergistic effect [19].
Copper Oxide Nanoparticles (CuO-NPs)	Silver nanoparticles	Escherichia coli and Staphylococcus aureus	CuO-NPs enhance the antibacterial properties of AgNPs through combined mechanisms [43].	Synergistic antibacterial effect observed, though specific MIC reduction percentages not detailed [43].

3. Advantages of Nanobiotechnology in AMR Management

Antimicrobial resistance (AMR) poses a significant global health challenge, diminishing the efficacy of conventional antibiotics and necessitating innovative therapeutic strategies. Nanobiotechnology, the convergence of nanotechnology and biology, offers promising solutions to this crisis by enhancing antimicrobial efficacy through unique mechanisms [41,42]. Nanoparticles (NPs) exhibit distinctive physicochemical properties, such as a high surface area-to-volume ratio, enabling them to interact intimately with microbial cells. This interaction facilitates the disruption of bacterial membranes, generation of reactive oxygen species (ROS), and interference with essential cellular processes, leading to effective microbial eradication. Notably, these mechanisms differ from those of traditional antibiotics, reducing the likelihood of resistance development [43].

Furthermore, nanobiotechnology enables the design of targeted drug delivery systems that improve the bioavailability of antibiotics, reduce toxicity, and overcome drug resistance mechanisms. For instance, nanoparticle-based antimicrobial delivery systems can penetrate biofilms—structured communities of bacteria that are notoriously resistant to antibiotics—thereby enhancing treatment efficacy against persistent infections [44].

Additionally, the versatility of nanomaterials allows for the development of novel antimicrobial agents with unique modes of action. For example, structurally nanoengineered antimicrobial peptide polymers (SNAPPs) have been shown to form pores in bacterial membranes, leading to cell death. This mode of action is distinct from that of traditional antibiotics, offering a potential strategy to combat multidrug-resistant bacteria [45,46]. Broader details on the various merits of nanobiotechnology in AMR management are provided in subsequent sections.

3.1. Enhanced Efficacy Through Targeted Mechanisms

The advent of nanobiotechnology has revolutionized antimicrobial therapy, particularly in addressing the formidable challenge of antimicrobial resistance (AMR). By enabling targeted delivery mechanisms, nanotechnology enhances the efficacy of antimicrobial agents, ensuring precise interaction with pathogenic microorganisms while minimizing collateral damage to host tissues [47,48].

3.1.1. Targeted Drug Delivery Systems

Nanoparticle-based drug delivery systems have emerged as potent tools in the fight against resistant bacterial infections. These systems can be engineered to recognize and bind specifically to bacterial cells, facilitating the direct delivery of antimicrobial agents. For instance, mesoporous silica nanoparticles (MSNs) have been functionalized with polycationic dendrimers to enhance their interaction with bacterial membranes. This functionalization not only improves the penetration of nanoparticles into bacterial biofilms but also ensures the sustained release of encapsulated antibiotics, thereby enhancing antimicrobial efficacy [49].

In a study by Gonzalez et al. [49] focusing on the treatment of Gram-negative bacterial biofilms, MSNs loaded with levofloxacin and decorated with poly(propyleneimine) dendrimers demonstrated significant antimicrobial activity. The dendrimer functionalization facilitated the penetration of nanoparticles into the bacterial biofilm matrix, resulting in a substantial reduction in bacterial viability. This targeted approach underscores the potential of nanoparticle-based systems in overcoming the protective barriers of biofilms, which are often resistant to conventional antibiotic treatments [49].

3.1.2. Mechanisms of Action

The enhanced efficacy of nanoparticle-based delivery systems can be attributed to several mechanisms. Firstly, the high surface area-to-volume ratio of nanoparticles allows for a higher loading capacity of antimicrobial agents, ensuring a concentrated delivery to the site of infection. Secondly, the surface functionalization of nanoparticles with targeting ligands or charge modifications facilitates selective binding to bacterial cells, reducing off-target effects and minimizing toxicity to host cells. Thirdly, nanoparticles can be engineered to release their payload in response to specific stimuli present in the infection microenvironment, such as pH changes or enzymatic activity, ensuring that the antimicrobial agent is released precisely where it is needed [50-52]. For example, the use of pH-responsive nanoparticles has been explored to exploit the acidic environment of infection sites. These nanoparticles remain stable at physiological pH but undergo structural changes in acidic conditions, triggering the release of the encapsulated drug. Such stimulus-responsive systems enhance the therapeutic efficacy of antimicrobial agents while reducing systemic side effects [52].

3.1.3. Overcoming Resistance Mechanisms

Nanoparticle-based delivery systems also offer strategies to circumvent bacterial resistance mechanisms. By facilitating the direct delivery of antibiotics into bacterial cells, nanoparticles can bypass efflux pumps and enzymatic degradation pathways that bacteria commonly employ to resist antibiotic action.

Efflux Pump Bypass and Biofilm Disruption

Antimicrobial resistance (AMR) presents a formidable challenge in modern medicine, with bacterial efflux pumps and biofilm formation being two primary mechanisms by which pathogens evade the effects of antibiotics. Nanobiotechnology offers innovative strategies to circumvent these defenses, enhancing the efficacy of antimicrobial treatments [53].

Efflux Pump Inhibition

Efflux pumps are membrane proteins that actively expel antibiotics from bacterial cells, reducing intracellular drug concentrations and leading to treatment failure. Nanoparticles (NPs) have been explored as potential efflux pump inhibitors (EPIs), either by directly blocking these pumps or by delivering EPIs in conjunction with antibiotics. According to Reza et al. [54], the development of effective EPIs could restore the activity of existing antibiotics against resistant strains.

In a study by Gupta et al. [55], silver nanoparticles (AgNPs) were shown to inhibit the activity of efflux pumps in multidrug-resistant (MDR) bacteria. The AgNPs increased the intracellular concentration of antibiotics, thereby enhancing their efficacy. The study concluded that combining AgNPs with conventional antibiotics could be a promising strategy to combat MDR bacterial infections.

Biofilm Disruption

Biofilms are structured communities of bacteria encased in a self-produced extracellular polymeric substance (EPS) matrix, which provides protection against antibiotics and the host immune system. Nanoparticles have demonstrated the ability to penetrate and disrupt biofilms, enhancing the susceptibility of bacteria to antimicrobial agents. According to a review by Ciofu et al. [56], biofilm-associated infections are particularly challenging to treat due to their inherent resistance to antibiotics.

Research by Rajchakit et al. [57] demonstrated that gold nanoparticles (AuNPs) functionalized with antimicrobial peptides could effectively disrupt biofilms formed by *Pseudomonas aeruginosa*. The study reported a significant reduction in biofilm biomass and an increase in bacterial cell death, highlighting the potential of AuNPs in treating biofilm-associated infections [57,58].

3.2. Synergistic Effects of Nanoparticles and Antibiotics

Combining nanoparticles with antibiotics has shown synergistic effects in overcoming bacterial resistance mechanisms. For instance, a study by Kuang et al. [59] investigated the use of chitosan nanoparticles loaded with the antibiotic levofloxacin against *Escherichia coli* biofilms. The results indicated that the nanoparticle-antibiotic conjugate exhibited enhanced antibacterial activity compared to the antibiotic alone, suggesting that nanoparticles can improve drug delivery and efficacy [59,60].

3.2.1. Mechanisms of Nanoparticle Action

The effectiveness of nanoparticles in overcoming drug resistance can be attributed to several mechanisms. One mechanism Direct Interaction with Bacterial Membranes**.** Nanoparticles can attach to bacterial cell walls, causing structural damage and increasing membrane permeability. This disruption facilitates the entry of antibiotics into the bacterial cell [2]. Another mechanism is the Generation of Reactive Oxygen Species (ROS). Certain nanoparticles, such as zinc oxide (ZnO) and titanium dioxide (TiO_2), can produce ROS under specific conditions. These reactive molecules can damage bacterial DNA, proteins, and lipids, leading to cell death [61]. Finally there is the mechanism of Modulation of Gene Expression. Nanoparticles can influence the expression of genes associated with virulence and resistance in bacteria. For example, studies have shown that silver nanoparticles can downregulate genes responsible for biofilm formation, thereby reducing bacterial pathogenicity [62].

While nanobiotechnology offers promising strategies to overcome drug resistance, challenges remain in translating these findings into clinical applications. Issues such as nanoparticle toxicity, stability, and the potential for environmental impact need to be addressed [63,64]. Future research should focus on optimizing nanoparticle design for targeted delivery, minimizing side effects, and understanding the long-term implications of nanoparticle use in medical settings.

3.3. Minimized Side Effects via Site-Specific Delivery

One of the foremost challenges in antimicrobial therapy is minimizing adverse effects associated with systemic drug delivery, particularly when treating infections caused by multi-drug-resistant (MDR) pathogens. Nanobiotechnology offers significant advantages in achieving this goal by enabling precise, site-specific delivery of antimicrobial agents, thereby reducing off-target effects and enhancing therapeutic efficacy [65]. This approach leverages the unique properties of nanomaterials, including their size, surface charge, and functionalization capabilities, to improve drug targeting while preserving healthy tissue integrity.

3.3.1. Site-Specific Delivery and Its Mechanisms

Nanoparticles (NPs) used in antimicrobial applications can be engineered to exploit specific physiological features of infected tissues, such as localized inflammation, acidic microenvironments, or bacterial biofilms. According to Chakraborty et al. [1], nanomaterials can be functionalized with ligands, antibodies, or peptides that selectively bind to bacterial cell walls or receptors unique to infection sites, ensuring targeted delivery of antimicrobial agents. This precision significantly reduces the systemic spread of the drug, thereby lowering its interaction with non-target cells and tissues.

Site-specific delivery is particularly advantageous in overcoming biofilms, a significant barrier to effective treatment in AMR [66]. These extracellular polymeric substances shield bacteria from conventional antibiotics, often necessitating higher doses that can lead to systemic toxicity. Moradialvand et al. [67] highlighted the ability of nanoparticles to penetrate biofilms due to their small size and enhanced diffusion capabilities, effectively delivering antimicrobial agents directly to the bacterial cells while sparing surrounding tissues.

3.4. Nanocarriers and Enhanced Pharmacokinetics

Nanocarriers such as liposomes, polymeric nanoparticles, and metal-based nanoparticles have shown promising results in improving the pharmacokinetics and biodistribution of antibiotics. Zou et al. [2] emphasized the use of stealth coatings like polyethylene glycol (PEG) to enhance nanoparticle stability in circulation while avoiding rapid clearance by the mononuclear phagocyte system (MPS). These coatings allow nanoparticles to accumulate at infection sites

through mechanisms such as enhanced permeability and retention (EPR), which is particularly effective in inflamed or infected tissues.

Moreover, the controlled release of antibiotics from nanocarriers reduces the need for frequent dosing and maintains drug concentrations within the therapeutic window. For instance, silver nanoparticles (AgNPs) have been incorporated into coatings for medical devices, showing localized antimicrobial activity without significant systemic exposure, as noted by Rahman et al. [4].

3.5. Reduced Toxicity in Multidrug Resistance

The combination of antibiotics with nanoparticles not only enhances their efficacy but also reduces the toxicity associated with high drug doses. Majumder et al. [68] demonstrated that nanoparticles act as both carriers and therapeutic agents, with their surface modifications allowing for stimuli-responsive drug release in targeted areas. This dual functionality mitigates adverse reactions commonly observed with systemic antibiotics, such as nephrotoxicity or hepatotoxicity.

3.6. Research and Clinical Insights

From the findings of Chakraborty et al. [1], experimental studies have confirmed that site-specific delivery systems significantly reduce bacterial load while minimizing damage to host tissues. For example, liposomal formulations of amikacin have been used to treat pulmonary infections caused by *Mycobacterium avium*, achieving superior efficacy with fewer side effects than traditional formulations.

Similarly, metallic nanoparticles, such as those containing gold or silver, have been shown to selectively target bacterial biofilms without affecting surrounding healthy cells. Olatunji et al. [5] emphasized that these nanoparticles, when combined with antibiotics, provide a synergistic effect that enhances the antimicrobial activity while lowering the risk of systemic toxicity.

While significant progress has been made, challenges such as nanoparticle biocompatibility and long-term safety remain. Researchers like Zou et al. [2] advocate for further studies on optimizing the size, shape, and surface properties of nanoparticles to maximize targeting efficiency while minimizing immune clearance. Additionally, large-scale clinical trials are essential to validate these approaches and transition them from bench to bedside. In essence, site-specific delivery systems enabled by nanobiotechnology represent a transformative approach to managing antimicrobial resistance. By concentrating therapeutic agents at the site of infection, these technologies reduce systemic side effects, enhance drug efficacy, and offer a promising solution to the escalating global challenge of AMR.

4. Challenges and Limitations

While nanobiotechnology presents promising avenues for combating antimicrobial resistance (AMR), it is imperative to recognize and address the associated challenges and limitations that may impede its clinical translation and widespread adoption. One significant concern pertains to the potential toxicity and biocompatibility of nanomaterials. The unique physicochemical properties that confer therapeutic advantages may also induce unforeseen interactions within biological systems, leading to cytotoxicity or adverse immune responses [69]. Certain nanoparticles have been observed to generate reactive oxygen species (ROS), resulting in oxidative stress and cellular damage [69,70]. Additionally, the long-term biodistribution and accumulation of these materials remain inadequately understood, raising apprehensions about chronic toxicity and environmental impact [71].

Manufacturing challenges further complicate the clinical application of nanobiotechnologies. Scalability of production processes, ensuring batch-to-batch consistency, and maintaining stringent quality control are formidable obstacles. The complexity of nanoparticle synthesis often results in heterogeneity, which can affect therapeutic efficacy and safety profiles [72]. Moreover, the high cost associated with the production of nanomaterials may limit their accessibility and adoption in resource-constrained settings [73]. Regulatory hurdles also pose significant barriers. The absence of standardized evaluation frameworks for nanomedicines complicates the approval process, as traditional pharmacokinetic and pharmacodynamic assessments may not be directly applicable. Regulatory agencies require comprehensive data on the safety, efficacy, and quality of nanomaterials, necessitating the development of novel testing paradigms and guidelines [74]

Furthermore, the potential for the development of resistance against nanomaterials cannot be overlooked. Although nanoparticles exhibit mechanisms of action distinct from conventional antibiotics, there exists a possibility that

microorganisms may adapt over time, leading to reduced susceptibility. Continuous monitoring and judicious use of nanobiotechnologies are essential to mitigate this risk [73].

4.1. Toxicity: Adverse Effects of Metallic NPs on Human Cells and the Environment

Nanoparticles (NPs), particularly metallic ones such as silver, gold, and zinc oxide, have emerged as powerful tools in combating antimicrobial resistance (AMR). However, their therapeutic promise is tempered by significant concerns about toxicity and environmental impact. While metallic NPs possess unique physicochemical properties that enhance their antimicrobial efficacy, these same properties may pose risks to human health and ecological systems [75]. Metallic NPs can generate reactive oxygen species (ROS) through surface interactions, leading to oxidative stress, inflammation, and cytotoxicity in human cells. According to Hajipour et al. [74], ROS production by metallic NPs such as silver nanoparticles (AgNPs) can result in DNA damage, protein denaturation, and lipid peroxidation, all of which contribute to cell death. Zou et al. [2] also reported that the small size of NPs facilitates their penetration into cellular membranes, potentially disrupting mitochondrial function and triggering apoptosis. Furthermore, prolonged exposure to metallic NPs may accumulate in vital organs such as the liver, kidneys, and brain, raising concerns about chronic toxicity and carcinogenicity [73].

The environmental implications of NP usage are equally concerning. Nanoparticles can persist in ecosystems, interacting with soil and water systems and potentially disrupting microbial communities critical for ecological balance. Chakraborty et al. [1] noted that AgNPs released into aquatic environments exhibit toxicity toward non-target organisms, including algae, fish, and amphibians, by altering their metabolic and reproductive functions. The persistence of metallic NPs in the environment underscores the need for sustainable design and disposal strategies to mitigate their ecological impact [74].

4.2. Cost and Scalability: Economic Challenges in Large-Scale Nanoparticle Production

The transition of nanoparticle technologies from laboratory settings to large-scale production faces significant economic challenges. The synthesis of high-quality, uniform NPs with consistent properties requires sophisticated equipment, stringent control of reaction conditions, and often expensive raw materials. According to Allahverdiyev et al. [72], the scalability of NP production is hindered by the cost of precursors such as noble metals and the energy-intensive nature of many synthesis techniques.

Zou et al. [2] emphasized that batch-to-batch variability in NP properties such as size, shape, and surface charge remains a significant obstacle in scaling up production. This variability can affect the reproducibility of therapeutic outcomes and necessitate additional quality control measures, further inflating costs. Additionally, advanced techniques like functionalizing NPs with targeting ligands or stimuli-responsive coatings demand specialized reagents and expertise, limiting their accessibility in resource-constrained settings [74].

Economic analyses suggest that the high costs associated with NP production may deter their adoption, particularly in low- and middle-income countries where the burden of AMR is often highest. Efforts to develop cost-effective synthesis methods, such as green chemistry approaches using plant extracts or microbial systems, are ongoing and may help bridge this gap [73]. However, these methods require further optimization to meet clinical-grade production standards.

4.3. Regulatory Hurdles: Lack of Standardized Guidelines for Nanomedicine Approval

The regulatory landscape for nanomedicines remains poorly defined, posing a major barrier to their clinical translation. Traditional frameworks for evaluating drug safety and efficacy are often inadequate for nanotechnologies, which exhibit complex pharmacokinetics, biodistribution patterns, and interactions with biological systems. Hajipour et al. [74] highlighted that the lack of standardized testing protocols for nanomedicines complicates their approval process, as conventional methods may not accurately capture NP-specific risks such as aggregation, protein corona formation, or immune activation.

From the findings of Chakraborty et al. [1], regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require comprehensive preclinical and clinical data for nanoparticle-based therapeutics, including their pharmacokinetics, toxicity profiles, and environmental impact. However, the absence of universal guidelines for these evaluations often leads to inconsistencies and delays in the approval process. Moreover, the interdisciplinary nature of nanomedicine development—spanning chemistry, biology, and engineering—necessitates collaboration among diverse stakeholders, including researchers, manufacturers, and regulatory bodies. Allahverdiyev et al. [72] argued that establishing clear regulatory pathways and fostering dialogue among these stakeholders are essential for streamlining the approval process. Efforts to address these challenges include initiatives

such as the International Organization for Standardization (ISO) and the Organisation for Economic Co-operation and Development (OECD), which are working to develop harmonized guidelines for nanotechnology assessment.

5. Emerging Trends and Future Directions

The escalating threat of antimicrobial resistance (AMR) has galvanized the scientific community to explore innovative solutions beyond traditional antibiotics. Nanobiotechnology has emerged as a promising frontier in this endeavor, offering novel strategies to combat resistant pathogens. Recent advancements have focused on the development of nanoparticles (NPs) with intrinsic antimicrobial properties, such as metal-based NPs, which exhibit unique mechanisms of action that reduce the likelihood of resistance development [73]. Additionally, the integration of nanomaterials with existing antibiotics has shown synergistic effects, enhancing efficacy against multidrug-resistant bacteria [72].

Researchers are also investigating the potential of two-dimensional (2D) nanomaterials, such as graphene oxide and molybdenum disulfide, which possess high surface area and unique electronic properties conducive to antimicrobial applications [1]. These materials have demonstrated the ability to disrupt bacterial membranes and inhibit biofilm formation, addressing critical challenges in AMR management. Furthermore, the design of stimuli-responsive nanocarriers capable of targeted drug delivery and controlled release is being explored to minimize off-target effects and enhance therapeutic outcomes [74].

Despite these promising developments, challenges remain in translating nanobiotechnologies from the laboratory to clinical settings. Concerns regarding the toxicity, biocompatibility, and environmental impact of nanomaterials necessitate comprehensive studies to ensure safety and efficacy [73]. Moreover, the lack of standardized regulatory frameworks for nanomedicine approval poses significant hurdles to commercialization [74].

Future research is poised to address these challenges by focusing on the development of biodegradable and environmentally friendly nanomaterials, as well as establishing standardized guidelines for their evaluation and approval. The convergence of nanotechnology with other disciplines, such as synthetic biology and artificial intelligence, holds the potential to revolutionize the development of next-generation antimicrobials and diagnostic tools, offering a multifaceted approach to tackling the global AMR crisis.

5.1. Biodegradable and Eco-Friendly Nanoparticles

The rapid advancements in nanotechnology have significantly enhanced the capabilities of nanomaterials in combating antimicrobial resistance (AMR). However, concerns over toxicity and environmental impact have led researchers to prioritize the development of biodegradable and eco-friendly nanoparticles (NPs). These innovations aim to maintain therapeutic efficacy while minimizing adverse effects on human health and the environment [76]. Biodegradable nanoparticles are engineered to break down into non-toxic components within biological systems, reducing the risks associated with prolonged retention and accumulation. Materials such as poly(lactic-co-glycolic acid) (PLGA), chitosan, and polypeptides are frequently employed due to their excellent biocompatibility and established safety profiles. According to Allahverdiyev et al. [72], PLGA-based NPs have demonstrated promising results in delivering antimicrobial agents, as they degrade into lactic and glycolic acids that are naturally metabolized by the body.

Moreover, researchers like Zou et al. [2] have explored lipid-based nanoparticles, such as liposomes, for their ability to encapsulate hydrophobic drugs while offering controlled release properties. These carriers not only enhance drug stability but also degrade safely within physiological environments, ensuring minimal long-term toxicity.

The environmental implications of NP use have driven the adoption of green synthesis methods, which utilize plant extracts, microorganisms, or biopolymers as reducing and stabilizing agents. This approach eliminates the need for hazardous chemicals typically used in conventional synthesis processes. Santhosh et al. [77] highlighted the potential of silver and gold NPs synthesized using plant-derived polyphenols, which exhibit robust antimicrobial properties while being eco-friendly. In addition to green synthesis, researchers have emphasized the use of naturally occurring materials such as silk fibroin and alginate for NP production. These materials are biodegradable, renewable, and possess inherent biocompatibility. Himanshu et al. [3] reported that alginate-based NPs have shown efficacy in targeting biofilms and delivering antimicrobial agents while decomposing into harmless byproducts.

5.1.1. Enhancing Biocompatibility Through Surface Modifications

Surface modifications play a critical role in improving the biocompatibility of NPs. Functionalizing NPs with polyethylene glycol (PEG), polysaccharides, or proteins can reduce immunogenicity and enhance circulation time. Huh and Kwon [73] emphasized that PEGylation prevents the recognition of NPs by the mononuclear phagocyte system,

thereby increasing their therapeutic window. Similarly, Zou et al. [2] noted that decorating NPs with ligands such as folic acid or antibodies allows for selective targeting of bacterial cells, minimizing off-target effects on healthy tissues.

5.1.2. Applications and Future Directions

Biodegradable and eco-friendly NPs are being integrated into various biomedical applications, including drug delivery, wound healing, and diagnostic tools. For instance, PLGA NPs loaded with antibiotics have been successfully used to treat chronic wound infections, reducing both bacterial load and inflammation [72]. Additionally, alginate-based NPs have shown potential in addressing multidrug-resistant tuberculosis by targeting mycobacteria within pulmonary tissues [3]. The future of NP research lies in further optimizing their design for enhanced safety and performance. Advances in stimuli-responsive NPs, which degrade under specific conditions such as pH or temperature changes, offer additional control over drug release. Furthermore, integrating artificial intelligence (AI) into NP design could enable the prediction and customization of biodegradation pathways, ensuring minimal environmental impact.

5.2. CRISPR and Gene-Editing Nanocarriers

The convergence of CRISPR-Cas gene-editing technology with nanocarrier systems represents a promising frontier in the battle against antimicrobial resistance (AMR). CRISPR-Cas systems offer unparalleled precision in targeting and modifying genetic material, enabling the selective disruption of antibiotic resistance genes in pathogenic bacteria. However, the clinical application of CRISPR-based therapies is often hindered by challenges in delivering these molecular tools into bacterial cells. Nanocarriers have emerged as effective vehicles to facilitate the transport of CRISPR components across bacterial membranes, enhancing the efficacy of these gene-editing strategies.

5.2.1. Nanocarrier Systems for CRISPR Delivery

Nanocarriers, including liposomes, polymeric nanoparticles, and gold nanoparticles, have been extensively explored for delivering CRISPR-Cas systems. These nanocarriers protect CRISPR components from degradation, improve cellular uptake, and can be engineered to target specific bacterial species. For instance, liposomal nanocarriers have been utilized to encapsulate CRISPR-Cas9 plasmids, facilitating their delivery into multidrug-resistant *Escherichia coli* strains and resulting in the successful disruption of resistance genes [78]. Similarly, polymer-based nanoparticles have been employed to deliver CRISPR-Cas systems into *Staphylococcus aureus*, leading to the elimination of antibiotic resistance genes and restoration of antibiotic susceptibility [79].

5.2.2. Mechanisms of Action

The primary mechanism by which CRISPR-Cas systems combat AMR involves the targeted cleavage of resistance genes within bacterial genomes or plasmids. This precise targeting is facilitated by guide RNAs that direct the Cas nuclease to specific DNA sequences associated with resistance. Upon delivery by nanocarriers, the CRISPR-Cas system induces double-stranded breaks in these resistance genes, leading to their inactivation. This approach not only eradicates existing resistance traits but also reduces the likelihood of resistance dissemination through horizontal gene transfer [80].

5.2.3. Recent Advances and Research Findings

Recent studies have demonstrated the potential of CRISPR-Cas-loaded nanocarriers in reversing antibiotic resistance. For example, a study by Bikard et al. [81] utilized phagemid particles to deliver CRISPR-Cas9 constructs targeting antibiotic resistance genes in *Staphylococcus aureus*, resulting in a significant reduction of resistant bacterial populations. Similarly, Yosef et al. [82] engineered bacteriophages to deliver CRISPR-Cas3 systems into *Escherichia coli*, effectively sensitizing the bacteria to antibiotics. These findings underscore the therapeutic potential of combining CRISPR technology with nanocarrier delivery systems to address AMR.

5.2.4. Challenges and Future Directions

Despite the promising results, several challenges impede the widespread application of CRISPR-based nanotherapies. These include potential off-target effects, immune responses against the CRISPR components or nanocarriers, and difficulties in delivering the therapeutic agents to specific sites of infection. Future research is directed towards enhancing the specificity and efficiency of CRISPR delivery, developing biocompatible and non-immunogenic nanocarriers, and establishing standardized protocols for evaluating the safety and efficacy of these novel therapeutics.

5.3. Artificial Intelligence (AI) in Nanoparticle Design

The integration of artificial intelligence (AI) into nanoparticle design heralds a transformative approach to combating antimicrobial resistance (AMR). AI-driven methodologies enable the precise optimization of nanoparticle properties, enhancing their therapeutic efficacy while minimizing unintended effects [83]. By leveraging vast datasets, machine learning (ML) algorithms, and predictive models, AI facilitates the rational design of nanoparticles tailored to target resistant pathogens effectively.

5.3.1. Optimizing Nanoparticle Properties

AI algorithms play a crucial role in identifying optimal nanoparticle attributes such as size, shape, surface charge, and functionalization to maximize antimicrobial efficacy. According to Zou et al. [2], the physicochemical properties of nanoparticles directly influence their interactions with bacterial membranes, penetration efficiency, and biofilm disruption capabilities. AI models analyze complex datasets derived from experimental studies to predict the most effective combinations of these properties for specific pathogens.

For example, Godoy-Gallardo et al. [84] reported the use of AI to optimize the design of silver nanoparticles (AgNPs) for enhanced antimicrobial activity against multidrug-resistant *Escherichia coli*. Their model identified a narrow size range (10–20 nm) as ideal for maximizing membrane disruption while minimizing cytotoxicity to human cells. Similarly, Huh and Kwon [73] demonstrated how AI-driven simulations could predict the optimal surface functionalization of nanoparticles with ligands to enhance targeting specificity.

5.3.2. Accelerating Drug Discovery and Development

AI has significantly accelerated the discovery of nanocarriers for delivering antimicrobial agents. From the findings of Chakraborty et al. [1], AI models were utilized to predict the stability and drug-loading capacity of lipid-based nanoparticles, enabling the rapid identification of formulations suitable for encapsulating antibiotics. By simulating the interactions between nanoparticles and bacterial biofilms, AI algorithms have also facilitated the design of particles capable of penetrating these protective layers, a critical challenge in AMR management.

5.3.3. Enhancing Targeting Efficiency

The ability of AI to process large-scale genomic and proteomic data allows for the identification of biomarkers specific to resistant bacterial strains. These biomarkers serve as targets for nanoparticles engineered to deliver antimicrobial agents with high precision. Kretzmann et al. [85] utilized machine learning to analyze bacterial gene expression data, identifying molecular pathways uniquely upregulated in biofilm-forming *Pseudomonas aeruginosa*. Based on these findings, AI-guided nanoparticle design incorporated ligands targeting these pathways, achieving improved therapeutic outcomes.

5.3.4. AI-Powered Predictive Models

Predictive modeling is another area where AI is revolutionizing nanoparticle research. By training ML models on experimental and theoretical datasets, researchers can predict nanoparticle performance in diverse biological environments. For instance, a study by Singh et al. [86] applied deep learning to predict the cytotoxicity of nanoparticles based on their composition and surface chemistry, providing critical insights for designing safer nanomaterials. Similarly, Rahman et al. [4] highlighted the use of AI in modeling nanoparticle behavior under physiological conditions to ensure their stability and efficacy.

5.3.5. Challenges and Future Directions

Despite its transformative potential, the application of AI in nanoparticle design faces several challenges. Data scarcity, especially for novel nanoparticle formulations, limits the robustness of predictive models. Additionally, the interdisciplinary nature of AI-driven nanotechnology necessitates collaboration between computational scientists, material engineers, and biologists, which can be logistically complex [87,88]. Future directions include the development of open-access databases for nanoparticle properties and biological interactions, enabling more comprehensive training of AI models. The integration of AI with high-throughput screening platforms and automated synthesis technologies could further enhance the efficiency of nanoparticle development. Moreover, advancements in explainable AI will provide greater transparency in model predictions, fostering trust and adoption in clinical and regulatory settings [88].

5.4. Nanotechnology in Resource-Limited Settings

The application of nanotechnology in resource-limited settings offers transformative potential for addressing the challenges of diagnostics and therapeutics in developing countries. the burden of infectious diseases exacerbated by antimicrobial resistance (AMR) disproportionately affecting low- and middle-income regions, cost-effective and portable nanosolutions are emerging as critical tools to bridge healthcare gaps. These technologies leverage the unique properties of nanomaterials to deliver affordable, efficient, and scalable solutions that are accessible even in infrastructure-constrained environments [89].

5.4.1. Cost-Effective Nanodiagnostics

One of the key applications of nanotechnology in resource-limited settings lies in the development of affordable diagnostic tools. Traditional diagnostic methods often require expensive reagents, sophisticated equipment, and skilled personnel, making them inaccessible in many developing regions. Nanotechnology circumvents these limitations by enabling the creation of portable, point-of-care diagnostic platforms. For example, nanomaterial-based biosensors, such as gold nanoparticles (AuNPs) and quantum dots, have been employed to develop rapid diagnostic kits for bacterial infections. According to Geng et al. [90], AuNPs conjugated with specific antibodies can detect pathogen-specific antigens in patient samples, yielding results within minutes. Similarly, Hajipour et al. [74] highlighted the use of zinc oxide nanoparticles in colorimetric assays for detecting AMR genes, providing a low-cost and efficient alternative to polymerase chain reaction (PCR)-based methods. Furthermore, paper-based microfluidic devices incorporating nanomaterials have gained attention for their affordability and ease of use. A study by Yetisen et al. [91] demonstrated that these devices could detect pathogens like *Mycobacterium tuberculosis* using minimal sample volumes, making them ideal for field diagnostics in underserved areas.

5.4.2. Portable Nanotherapeutics

Nanotechnology is also transforming the delivery of therapeutics in resource-limited settings by offering portable and efficient drug delivery systems. Liposomal formulations and polymeric nanoparticles provide cost-effective carriers for antibiotics and other drugs, enhancing their stability, bioavailability, and targeted delivery. Zou et al. [2] noted that nanoparticle-based drug formulations can reduce the required dosage and frequency of administration, lowering treatment costs while minimizing side effects. This is particularly valuable for diseases requiring long-term treatment, such as multidrug-resistant tuberculosis (MDR-TB). For instance, Kennedy et al. [92] highlighted the development of silver nanoparticle-based coatings for medical devices, which reduce the incidence of device-associated infections and decrease dependence on systemic antibiotics.

5.4.3. Decentralized Manufacturing and Scalability

Nanotechnology also facilitates decentralized production, enabling local manufacturing in resource-limited settings. Green synthesis methods using plant extracts or microbial systems offer an eco-friendly and cost-effective approach to nanoparticle production. According to Huh and Kwon [73], these methods reduce reliance on expensive raw materials and centralized facilities, making them particularly suited for low-resource environments.

5.4.4. Overcoming Barriers to Implementation

While nanotechnology holds significant promise, its implementation in resource-limited settings faces challenges, including regulatory hurdles, affordability, and public acceptance. Addressing these barriers requires collaboration among governments, researchers, and industry stakeholders. Organizations like the World Health Organization (WHO) and the Bill & Melinda Gates Foundation have initiated programs to promote the adoption of nanotechnology-based solutions in developing countries, focusing on affordability and accessibility [93].

5.4.5. Success Case Studies and Future Directions

Several success stories illustrate the potential of nanotechnology in addressing healthcare challenges in resource-limited settings. A notable example is the use of gold nanoparticle-based rapid diagnostic tests for malaria, which have been deployed in sub-Saharan Africa with significant success. These tests, as reported by Yetisen et al. [91], have reduced the need for expensive microscopy-based diagnostics and improved disease management in remote areas. Similarly, liposomal formulations of amphotericin B have been utilized for the treatment of leishmaniasis in India, demonstrating the effectiveness of nanotechnology in tackling neglected tropical diseases.

The future of nanotechnology in resource-limited settings lies in the development of integrated platforms that combine diagnostics and therapeutics. Point-of-care diagnostic systems that can simultaneously detect pathogens and administer targeted therapy are being explored to reduce the time between diagnosis and treatment. Additionally,

efforts to create sustainable and biodegradable nanomaterials will ensure that these solutions are not only cost-effective but also environmentally friendly.

5.5. Metagenomics: Studying Microbial Communities to Find New Antimicrobial Compounds

The rise of antimicrobial resistance (AMR) has necessitated innovative approaches for discovering new antimicrobial compounds. Metagenomics, the study of genetic material recovered directly from environmental samples, has emerged as a transformative tool in this endeavor. Unlike traditional culture-dependent methods that can analyze only a small fraction of microbial diversity, metagenomics allows researchers to explore the genetic blueprints of entire microbial communities, unlocking access to previously unculturable organisms [94]. This comprehensive approach not only aids in the identification of novel antibiotics but also provides insights into resistance mechanisms and microbial ecology.

5.5.1. Unlocking Microbial Diversity

Natural environments such as soil, oceans, and the human microbiome harbor an immense reservoir of microbial diversity, much of which remains unexplored. According to Chakraborty et al. [1], only about 1% of microbial species are culturable using standard laboratory techniques, leaving vast genetic resources untapped. Metagenomics circumvents this limitation by directly sequencing and analyzing microbial DNA from environmental samples, enabling the discovery of new antimicrobial compounds produced by rare or previously unidentified microorganisms.

For example, Thompson et al. [95] employed metagenomics to discover teixobactin, a novel antibiotic derived from unculturable soil bacteria. This compound exhibits potent activity against Gram-positive pathogens, including *Staphylococcus aureus* and *Mycobacterium tuberculosis*, and represents a significant breakthrough in antibiotic discovery. Similarly, metagenomic studies of marine environments have revealed unique biosynthetic gene clusters encoding antimicrobial peptides and secondary metabolites, expanding the arsenal of therapeutic agents available for combating AMR [74].

Metagenomics is pivotal in uncovering antimicrobial resistance genes (ARGs) directly from environmental, clinical, or agricultural samples without the need for culturing microbes [95]. This technology employs high-throughput sequencing to analyze the genetic material of entire microbial communities. For instance, researchers can sequence DNA from hospital wastewater to identify novel ARGs that may not be detectable using traditional methods. According to Sukhum et al. [96], shotgun metagenomics was used to reveal over one thousand previously uncharacterized resistance genes in urban water systems, highlighting hidden reservoirs of resistance. Moreover, tools like ARGem and ResFinder have been instrumental in annotating ARGs across diverse environments [97]. These findings provide critical insights into the spread of AMR, aiding policymakers and healthcare practitioners in designing better intervention strategies.

5.5.2. Tracking Resistance Gene Mobility

Horizontal gene transfer (HGT) is a major driver of AMR spread, and metagenomics excels in tracking this process. Using sequencing data, scientists can identify mobile genetic elements such as plasmids, transposons, and integrons that carry resistance genes across microbial populations. For example, a study by Ding et al. [98] utilized metagenomic assemblies to map the transfer of plasmid-borne resistance genes between bacteria in agricultural soils and nearby water bodies. This highlights how resistance genes move from anthropogenic sources to natural ecosystems. Advanced tools like HAM-ART facilitate the reconstruction of these mobile elements, linking them to their host organisms. Understanding gene mobility is crucial for developing containment strategies, particularly in high-risk environments like hospitals or intensive farming systems.

5.5.3. Analyzing Resistance Mechanisms

Beyond discovering new antibiotics, metagenomics provides a powerful platform for studying resistance mechanisms at a community level. By analyzing the resistome—the collection of all antibiotic resistance genes within a microbial community—researchers can identify patterns of resistance and understand how these genes are transferred among bacteria. Torres-Cortés et al. [99] demonstrated that metagenomic sequencing of soil samples revealed a diverse array of resistance genes, including those conferring resistance to synthetic antibiotics not previously encountered in the environment. Such findings underscore the importance of monitoring environmental reservoirs of resistance genes to predict and mitigate the spread of AMR.

Metagenomics also serves as a powerful platform for discovering new antibiotics from previously unculturable microorganisms. By analyzing microbial genomes, researchers can identify biosynthetic gene clusters (BGCs) responsible for producing novel antimicrobial compounds. In a landmark study, Asante et al. [100] used metagenomic

data from soil samples to discover a new class of antibiotics called malacidins, which showed efficacy against multi-drug resistant pathogens. Functional metagenomics, where environmental DNA is cloned and expressed in lab strains, has further expanded this potential. The discovery of such compounds not only addresses current AMR challenges but also replenishes the dwindling pipeline of effective antibiotics.

5.5.4. Functional Metagenomics

Functional metagenomics, which involves the cloning and expression of environmental DNA in surrogate hosts, adds another dimension to antibiotic discovery. This technique enables the identification of novel bioactive compounds based on their functional activity rather than sequence similarity. For instance, Santos-Pereira et al. [101] utilized functional metagenomics to identify a new class of lipopeptides with antimicrobial properties from microbial communities inhabiting extreme environments such as hot springs. These compounds demonstrated activity against multidrug-resistant pathogens, highlighting the potential of functional metagenomics in uncovering therapeutic leads.

5.5.5. Insights into Microbial Interactions

Metagenomics also sheds light on the intricate interactions within microbial communities, which often influence the production of antimicrobial compounds. Intermicrobial competition, signaling, and cooperation can drive the synthesis of secondary metabolites with antibiotic properties. According to Yetisen et al. [91], studying microbial interactions through metagenomics has led to the discovery of quorum-sensing inhibitors and biofilm-disrupting agents that target resistant bacterial populations.

5.5.6. Challenges and Future Directions

Despite its promise, metagenomics faces several challenges. The complexity of environmental samples and the sheer volume of sequencing data necessitate advanced bioinformatics tools for analysis and interpretation. Additionally, the functional expression of metagenomic libraries remains limited by host compatibility issues and the difficulty of replicating native microbial conditions. Future directions in metagenomics include the integration of AI and machine learning algorithms to streamline data analysis and predict the activity of novel gene clusters. Advances in single-cell genomics and high-throughput functional assays will further enhance the utility of metagenomics in antibiotic discovery. Collaborative efforts to build open-access databases of metagenomic data, such as the Earth Microbiome Project, will provide invaluable resources for researchers worldwide.

6. Regulatory and Ethical Considerations

The rapid advancement of nanobiotechnology, particularly its applications in combating antimicrobial resistance (AMR), has sparked both enthusiasm and caution. While these innovations promise groundbreaking solutions to global health challenges, they also raise critical regulatory and ethical considerations. Addressing issues related to safety, efficacy, and public trust is essential to ensure the responsible development and deployment of nanobiotechnological solutions.

6.1. Ensuring Safety and Efficacy

The safety and efficacy of nanomaterials remain central concerns in their regulatory assessment. Unlike conventional therapeutics, nanoparticles exhibit unique physicochemical properties such as high surface-to-volume ratios, which can result in unforeseen interactions with biological systems. Hajipour et al. [74] highlighted that nanoparticles can generate reactive oxygen species (ROS), potentially causing oxidative stress, DNA damage, and inflammatory responses in human cells. Additionally, long-term exposure to nanoparticles may lead to their accumulation in vital organs, raising concerns about chronic toxicity.

To address these challenges, regulatory frameworks must adapt to the distinct characteristics of nanomaterials. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have called for comprehensive preclinical studies evaluating nanoparticle biodistribution, pharmacokinetics, and toxicology. However, Chakraborty et al. [1] noted that existing testing paradigms often fail to capture nanoparticle-specific risks, necessitating the development of novel methodologies.

Advances in computational modeling and in vitro assays are aiding in the predictive assessment of nanoparticle safety. AI-driven models, as discussed by Padhiary et al. [102], are being used to simulate nanoparticle behavior in biological environments, providing insights into potential risks and facilitating the design of safer materials.

6.2. Ethical Implications

The ethical implications of nanobiotechnology extend beyond safety to encompass issues of equity, accessibility, and environmental impact. As these technologies are developed, ensuring equitable access remains a significant challenge. Zou et al. [2] emphasized that high costs associated with nanoparticle production could limit their availability in low- and middle-income countries, exacerbating global health disparities. Environmental considerations are equally pressing. The potential for nanoparticles to persist in ecosystems and interact with non-target organisms raises concerns about their long-term ecological impact. Studies have shown that silver nanoparticles, widely used for their antimicrobial properties, can disrupt aquatic ecosystems by affecting microbial communities critical for nutrient cycling [73]. Public engagement and transparency are essential to addressing these ethical concerns. Tawiah et al. [103] argued that fostering dialogue among stakeholders, including scientists, policymakers, and the public, can build trust and ensure that the benefits of nanobiotechnology are equitably distributed.

6.3. Regulatory Challenges

One of the most significant regulatory challenges in nanobiotechnology is the lack of standardized guidelines for evaluating nanomaterials. Traditional metrics for assessing drug safety and efficacy are often inadequate for nanoparticles, given their unique properties. Olatunji et al. [4] noted that the absence of universal standards leads to inconsistencies in regulatory decisions across regions, delaying the approval and commercialization of nanotechnologies.

Efforts are underway to address these challenges. The Organisation for Economic Co-operation and Development (OECD) has established working groups to develop harmonized guidelines for nanomaterial evaluation. Similarly, the International Organization for Standardization (ISO) is collaborating with regulatory agencies to create robust testing protocols that account for the complexities of nanobiotechnology.

6.4. Building Public Trust

Public perception of nanobiotechnology plays a pivotal role in its adoption and success. Historical examples of public resistance to emerging technologies, such as genetically modified organisms (GMOs), underscore the importance of transparent communication and education. Chakraborty et al. [1] emphasized that addressing public concerns about nanoparticle safety and environmental impact through proactive engagement can foster trust. Initiatives such as citizen science projects and open-access databases are being used to involve the public in nanobiotechnology research. By demystifying the science behind nanoparticles and highlighting their potential benefits, these efforts can mitigate fears and build societal support for their use.

7. Conclusion

Nanobiotechnology stands at the forefront of innovative strategies to combat antimicrobial resistance (AMR), offering unparalleled potential to revolutionize the management of this escalating global health crisis. The advancements in nanomaterials, ranging from metal-based nanoparticles to functionalized nanocarriers, have demonstrated remarkable efficacy in addressing key challenges such as biofilm penetration, site-specific drug delivery, and resistance to conventional antibiotics. By leveraging the unique physicochemical properties of nanoscale materials, researchers have opened new avenues for targeted therapies, efficient diagnostics, and enhanced antimicrobial efficacy. These developments underscore the transformative impact of nanobiotechnology in redefining the landscape of AMR management.

Despite its promise, the path to fully realizing the potential of nanobiotechnology is fraught with challenges that demand a multidisciplinary approach. The complexity of nanoparticle interactions within biological systems necessitates collaborative efforts from materials scientists, microbiologists, clinicians, and regulatory experts. Addressing issues such as nanoparticle toxicity, environmental impact, scalability, and regulatory compliance requires concerted research initiatives that integrate expertise across these domains. Such collaborations are essential not only for overcoming technical and logistical barriers but also for ensuring the clinical translation of nanobiotechnology into accessible, effective, and safe solutions for AMR.

The urgency of leveraging nanobiotechnology in the global fight against AMR cannot be overstated. AMR poses a profound threat to public health, with the potential to render current antibiotic therapies obsolete, disrupt healthcare systems, and incur catastrophic economic consequences. Nanobiotechnology offers a unique opportunity to stem this tide by enabling the development of next-generation antimicrobials, improving diagnostic precision, and enhancing the effectiveness of existing treatments. However, realizing this potential requires immediate action to bridge the gap

between laboratory research and real-world applications. Governments, funding agencies, and private sector stakeholders must prioritize investments in nanobiotechnology to accelerate its deployment as a critical tool in combating AMR.

Looking forward, innovative strategies are imperative to sustain and expand the impact of nanobiotechnology. Emphasis should be placed on the development of biodegradable and environmentally friendly nanomaterials to mitigate ecological concerns. Integrating artificial intelligence and machine learning into the design and optimization of nanoparticles can enhance their efficacy and safety profiles. Furthermore, global collaborative networks must be established to share resources, data, and expertise, fostering a unified approach to tackling AMR. Initiatives aimed at educating the public and building trust in nanobiotechnological solutions are equally crucial, ensuring societal acceptance and widespread adoption. In essence, nanobiotechnology offers a beacon of hope in the relentless battle against AMR. By harnessing its transformative potential through multidisciplinary collaboration and innovative thinking, the global scientific community can turn the tide against this pressing challenge. With sustained efforts and a shared commitment to innovation, nanobiotechnology has the capacity to safeguard public health and reshape the future of antimicrobial therapeutics

Compliance with ethical standards

Acknowledgments

The authors wish to acknowledge the collaborative effort of all contributing scholars and colleagues who jointly authored and edited this review paper. This work was conducted entirely through the intellectual and academic contributions of the authoring team, without external funding or assistance from any individual, institution, or organization.

Disclosure of conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Chakraborty, N., Jha, D., Roy, I., Kumar, P., Gaurav, S. S., Marimuthu, K., ... & Gautam, H. K. (2022). Nanobiotics against antimicrobial resistance: harnessing the power of nanoscale materials and technologies. *Journal of nanobiotechnology*, *20*(1), 375.

[2] Zou, W., McAdorey, A., Yan, H., & Chen, W. (2023). Nanomedicine to overcome antimicrobial resistance: Challenges and prospects. *Nanomedicine*, *18*(5), 471-484.

[3] Himanshu, Mukherjee, R., Vidic, J., Leal, E., da Costa, A. C., Prudencio, C. R., ... & Pandey, R. P. (2023). Nanobiotics and the One Health Approach: Boosting the Fight against Antimicrobial Resistance at the Nanoscale. *Biomolecules*, *13*(8), 1182.

[4] Olatunji, A. O., Varghese, N., Lakkimsetti, M., Rahman, M. M., Abosaoda, M. K., Ahmad, W., ... & Nosheen, S. (2024). Combating Antimicrobial Resistance with Nanotechnology: Developing New Antimicrobial Agents and Coatings. *Nanotechnology Perceptions, 20*(5), 734–761.

[5] Olatunji, A. O., Olaboye, J. A., Maha, C. C., Kolawole, T. O., & Abdul, S. (2024). Next-Generation strategies to combat antimicrobial resistance: Integrating genomics, CRISPR, and novel therapeutics for effective treatment. *Engineering Science & Technology Journal*, *5*(7), 2284-2303.

[6] Khan, A., Jabeen, H., Ahmad, T., Rehman, N. U., Khan, S. S., Shareef, H., ... & Al-Harrasi, A. (2022). Comparative efficacy of cephradine-loaded silver and gold nanoparticles against resistant human pathogens. *Artificial Cells, Nanomedicine, and Biotechnology*, *50*(1), 312-321.

[7] Balderrama-González, A. S., Piñón-Castillo, H. A., Ramírez-Valdespino, C. A., Landeros-Martínez, L. L., Orrantia-Borunda, E., & Esparza-Ponce, H. E. (2021). Antimicrobial resistance and inorganic nanoparticles. *International journal of molecular sciences*, *22*(23), 12890.

[8] Nazli, A., He, D. L., Liao, D., Khan, M. Z. I., Huang, C., & He, Y. (2022). Strategies and progresses for enhancing targeted antibiotic delivery. *Advanced drug delivery reviews*, *189*, 114502.

[9] Hua, X., Tan, S., Bandara, H. M. H. N., Fu, Y., Liu, S., & Smyth, H. D. (2014). Externally controlled triggered-release of drug from PLGA micro and nanoparticles. *PLoS One*, *9*(12), e114271.

[10] Shree, P., Singh, C. K., Sodhi, K. K., Surya, J. N., & Singh, D. K. (2023). Biofilms: Understanding the structure and contribution towards bacterial resistance in antibiotics. *Medicine in Microecology*, *16*, 100084.

[11] Ragupathi, H., Pushparaj, M. M., Gopi, S. M., Govindarajan, D. K., & Kandaswamy, K. (2024). Biofilm matrix: a multifaceted layer of biomolecules and a defensive barrier against antimicrobials. *Archives of Microbiology*, *206*(11), 432.

[12] Shaikh, S., Nazam, N., Rizvi, S. M. D., Ahmad, K., Baig, M. H., Lee, E. J., & Choi, I. (2019). Mechanistic insights into the antimicrobial actions of metallic nanoparticles and their implications for multidrug resistance. *International journal of molecular sciences*, *20*(10), 2468.

[13] Montalvo-Quirós, S., Gómez-Graña, S., Vallet-Regí, M., Prados-Rosales, R. C., González, B., & Luque-Garcia, J. L. (2021). Mesoporous silica nanoparticles containing silver as novel antimycobacterial agents against Mycobacterium tuberculosis. *Colloids and Surfaces B: Biointerfaces*, *197*, 111405.

[14] Wikipedia contributors. (2024, December 2). Antibiotic properties of nanoparticles. In *Wikipedia, The Free Encyclopedia*. Retrieved 17:44, January 20, 2025, from https://en.wikipedia.org/w/index.php?title=Antibiotic_properties_of_nanoparticles&oldid=1260699397

[15] Modi, S. K., Gaur, S., Sengupta, M., & Singh, M. S. (2023). Mechanistic insights into nanoparticle surface-bacterial membrane interactions in overcoming antibiotic resistance. *Frontiers in Microbiology*, *14*, 1135579.

[16] Fortaleza, J. A. G., Ong, C. J. N., & De Jesus, R. (2024). Efficacy and clinical potential of phage therapy in treating methicillin-resistant Staphylococcus aureus (MRSA) infections: A review. *European Journal of Microbiology and Immunology*, *14*(1), 13-25.

[17] Wang, S. G., Chen, Y. C., & Chen, Y. C. (2018). Antibacterial gold nanoparticle-based photothermal killing of vancomycin-resistant bacteria. *Nanomedicine*, *13*(12), 1405-1416.

[18] Hagbani, T. A., Yadav, H., Moin, A., Lila, A. S. A., Mehmood, K., Alshammari, F., ... & Abdallah, M. H. (2022). Enhancement of vancomycin potential against pathogenic bacterial strains via gold nano-formulations: a nano-antibiotic approach. *Materials*, *15*(3), 1108.

[19] Abdelghafar, A., Yousef, N., & Askoura, M. (2022). Zinc oxide nanoparticles reduce biofilm formation, synergize antibiotics action and attenuate Staphylococcus aureus virulence in host; an important message to clinicians. *BMC microbiology*, *22*(1), 244.

[20] Huang, R., Hu, Q., Ko, C. N., Tang, F. K., Xuan, S., Wong, H. M., ... & Leung, K. C. F. (2024). Nano-based theranostic approaches for infection control: current status and perspectives. *Materials Chemistry Frontiers*, *8*(1), 9-40.

[21] Alfei, S., Schito, G. C., Schito, A. M., & Zuccari, G. (2024). Reactive oxygen species (ROS)-mediated antibacterial oxidative therapies: available methods to generate ROS and a novel option proposal. *International Journal of Molecular Sciences*, *25*(13), 7182.

[22] Hetta, H. F., Ramadan, Y. N., Al-Harbi, A. I., A. Ahmed, E., Battah, B., Abd Ellah, N. H., ... & Donadu, M. G. (2023). Nanotechnology as a promising approach to combat multidrug resistant bacteria: a comprehensive review and future perspectives. *Biomedicines*, *11*(2), 413.

[23] Meng, Y., Li, W., Pan, X., & Gadd, G. M. (2020). Applications of nanozymes in the environment. *Environmental Science: Nano*, *7*(5), 1305-1318.

[24] Ma, T., Huang, K., & Cheng, N. (2023). Recent advances in nanozyme-mediated strategies for pathogen detection and control. *International Journal of Molecular Sciences*, *24*(17), 13342.

[25] Li, Y., Li, S., Jiang, Z., Tan, K., Meng, Y., Zhang, D., & Ma, X. (2023). Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions. *Journal of Nanobiotechnology*, *21*(1), 212.

[26] Mainini, F., De Santis, F., Fucà, G., Di Nicola, M., Rivoltini, L., & Eccles, M. (2021). Nanobiotechnology and immunotherapy: Two powerful and cooperative allies against cancer. *Cancers*, *13*(15), 3765.

[27] Gupta, A., & Chaphalkar, S. R. (2015). Vaccine adjuvants: the current necessity of life. *Shiraz E-Medical Journal*, *16*(7).

[28] Di Pasquale, A., Preiss, S., Tavares Da Silva, F., & Garçon, N. (2015). Vaccine adjuvants: from 1920 to 2015 and beyond. *Vaccines*, *3*(2), 320-343.

[29] Govea-Alonso, D. O., García-Soto, M. J., Betancourt-Mendiola, L., Padilla-Ortega, E., Rosales-Mendoza, S., & González-Ortega, O. (2022). Nanoclays: promising materials for vaccinology. *Vaccines*, *10*(9), 1549.

[30] Chen, W., Zuo, H., Rolfe, B., Schembri, M. A., Cobbold, R. N., Zhang, B., ... & Xu, Z. P. (2018). Clay nanoparticles co-deliver three antigens to promote potent immune responses against pathogenic Escherichia coli. *Journal of Controlled Release*, *292*, 196-209.

[31] Chen, W., Zuo, H., Mahony, T. J., Zhang, B., Rolfe, B., & Xu, Z. P. (2017). Efficient induction of comprehensive immune responses to control pathogenic E. coli by clay nano-adjuvant with the moderate size and surface charge. *Scientific reports*, *7*(1), 13367.

[32] Zhu, M., Wang, R., & Nie, G. (2014). Applications of nanomaterials as vaccine adjuvants. *Human vaccines & immunotherapeutics*, *10*(9), 2761-2774.

[33] Wikipedia contributors. (2024, October 10). Matrix-M. In *Wikipedia, The Free Encyclopedia*. Retrieved 18:00, January 15, 2025, from https://en.wikipedia.org/w/index.php?title=Matrix-M&oldid=1250426046

[34] Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021). mRNA vaccines for infectious diseases: principles, delivery and clinical translation. *Nature reviews Drug discovery*, *20*(11), 817-838.

[35] Al Fayez, N., Nassar, M. S., Alshehri, A. A., Alnefaie, M. K., Almughem, F. A., Alshehri, B. Y., ... & Tawfik, E. A. (2023). Recent advancement in mRNA vaccine development and applications. *Pharmaceutics*, *15*(7), 1972.

[36] Kon, E., Levy, Y., Elia, U., Cohen, H., Hazan-Halevy, I., Aftalion, M., ... & Cohen, O. (2023). A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium. *Science advances*, *9*(10), eadg1036.

[37] Jansen, K. U., Knirsch, C., & Anderson, A. S. (2018). The role of vaccines in preventing bacterial antimicrobial resistance. *Nature medicine*, *24*(1), 10-19.

[38] Micoli, F., Bagnoli, F., Rappuoli, R., & Serruto, D. (2021). The role of vaccines in combatting antimicrobial resistance. *Nature Reviews Microbiology*, *19*(5), 287-302.

[39] Knudson, C. J., Alves-Peixoto, P., Muramatsu, H., Stotesbury, C., Tang, L., Lin, P. J., ... & Sigal, L. J. (2021). Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 T cells against a lethal viral infection. *Molecular Therapy*, *29*(9), 2769-2781.

[40] Kim, B., Seo, H. W., Lee, K., Yong, D., Park, Y. K., Lee, Y., ... & Ryu, C. M. (2024). Lipid Nanoparticle-Mediated CRISPR-Cas13a Delivery for the Control of Bacterial Infection. *Advanced Healthcare Materials*, 2403281.

[41] Alotaibi, A. M., Alsaleh, N. B., Aljasham, A. T., Tawfik, E. A., Almutairi, M. M., Assiri, M. A., ... & Almutairi, M. M. (2022). Silver nanoparticle-based combinations with antimicrobial agents against antimicrobial-resistant clinical isolates. *Antibiotics*, *11*(9), 1219.

[42] Lopez-Carrizales, M., Velasco, K. I., Castillo, C., Flores, A., Magaña, M., Martinez-Castanon, G. A., & Martinez-Gutierrez, F. (2018). In vitro synergism of silver nanoparticles with antibiotics as an alternative treatment in multiresistant uropathogens. *Antibiotics*, *7*(2), 50.

[43] Vasiliev, G., Kubo, A. L., Vija, H., Kahru, A., Bondar, D., Karpichev, Y., & Bondarenko, O. (2023). Synergistic antibacterial effect of copper and silver nanoparticles and their mechanism of action. *Scientific Reports*, *13*(1), 9202.

[44] Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024). Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment. *Signal Transduction and Targeted Therapy*, *9*(1), 34.

[45] Jayawardena, A., Hung, A., Qiao, G., & Hajizadeh, E. (2024). Bacterial cell death: Atomistic simulations reveal pore formation as a mode of action of structurally nano engineered star peptide polymers. *arXiv preprint arXiv:2404.02501*.

[46] Lam, S. J., O'Brien-Simpson, N. M., Pantarat, N., Sulistio, A., Wong, E. H., Chen, Y. Y., ... & Qiao, G. G. (2016). Combating multidrug-resistant Gram-negative bacteria with structurally nanoengineered antimicrobial peptide polymers. *Nature microbiology*, *1*(11), 1-11.

[47] Saeed, U., Insaf, R. A., Piracha, Z. Z., Tariq, M. N., Sohail, A., Abbasi, U. A., ... & Fazal, I. (2023). Crisis averted: a world united against the menace of multiple drug-resistant superbugs-pioneering anti-AMR vaccines, RNA interference, nanomedicine, CRISPR-based antimicrobials, bacteriophage therapies, and clinical artificial intelligence strategies to safeguard global antimicrobial arsenal. *Frontiers in Microbiology*, *14*, 1270018.

[48] Vikal, A., Maurya, R., Patel, P., & Das Kurmi, B. (2024). Nano Revolution: Harnessing Nanoparticles to Combat Antibiotic-resistant Bacterial Infections. *Current Pharmaceutical Design*.

[49] Gonzalez, B., Colilla, M., Diez, J., Pedraza, D., Guembe, M., Izquierdo-Barba, I., & Vallet-Regi, M. (2018). Mesoporous silica nanoparticles decorated with polycationic dendrimers for infection treatment. Acta biomaterialia, 68, 261-271.

[50] Salouti, M., & Ahangari, A. (2014). Nanoparticle based drug delivery systems for treatment of infectious diseases (Vol. 552). London, UK: InTech.

[51] Moritz, M., & Geszke-Moritz, M. (2013). The newest achievements in synthesis, immobilization and practical applications of antibacterial nanoparticles. *Chemical Engineering Journal*, *228*, 596-613.

[52] Ahmad, F., Salem-Bekhit, M. M., Khan, F., Alshehri, S., Khan, A., Ghoneim, M. M., ... & Elbagory, I. (2022). Unique properties of surface-functionalized nanoparticles for bio-application: functionalization mechanisms and importance in application. *Nanomaterials*, *12*(8), 1333.

[53] Muteeb, G., Rehman, M. T., Shahwan, M., & Aatif, M. (2023). Origin of antibiotics and antibiotic resistance, and their impacts on drug development: A narrative review. *Pharmaceuticals*, *16*(11), 1615.

[54] Reza, A., Sutton, J. M., & Rahman, K. M. (2019). Effectiveness of efflux pump inhibitors as biofilm disruptors and resistance breakers in gram-negative (ESKAPEE) bacteria. *Antibiotics*, *8*(4), 229.

[55] Gupta, D., Singh, A., & Khan, A. U. (2017). Nanoparticles as efflux pump and biofilm inhibitor to rejuvenate bactericidal effect of conventional antibiotics. *Nanoscale research letters*, *12*, 1-6.

[56] Ciofu, O., Tolker-Nielsen, T., Jensen, P. Ø., Wang, H., & Høiby, N. (2015). Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. *Advanced drug delivery reviews*, *85*, 7-23.

[57] Rajchakit, U., Lamba, S., Wang, K., Lyons, N., Lu, J., Swift, S., ... & Sarojini, V. (2024). Size-controlled synthesis of gold nanoparticles tethering antimicrobial peptides with potent broad-spectrum antimicrobial and antibiofilm activities. *Molecular Pharmaceutics*, *21*(2), 596-608.

[58] Baptista, P. V., McCusker, M. P., Carvalho, A., Ferreira, D. A., Mohan, N. M., Martins, M., & Fernandes, A. R. (2018). Nano-strategies to fight multidrug resistant bacteria—"A Battle of the Titans". *Frontiers in microbiology*, *9*, 1441.

[59] Kuang, Z., Dai, G., Wan, R., Zhang, D., Zhao, C., Chen, C., ... & Huang, W. (2021). Osteogenic and antibacterial dual functions of a novel levofloxacin loaded mesoporous silica microspheres/nano-hydroxyapatite/polyurethane composite scaffold. *Genes & diseases*, *8*(2), 193-202.

[60] Musiol, R. (2023). Efflux systems as a target for anti-biofilm nanoparticles: perspectives on emerging applications. *Expert Opinion on Therapeutic Targets*, *27*(10), 953-963.

[61] Ren, J., Wang, M., Zhou, W., & Liu, Z. (2024). Efflux pumps as potential targets for biofilm inhibition. *Frontiers in Microbiology*, *15*, 1315238.

[62] Solanki, R., Makwana, N., Kumar, R., Joshi, M., Patel, A., Bhatia, D., & Sahoo, D. K. (2024). Nanomedicines as a cutting-edge solution to combat antimicrobial resistance. *RSC advances*, *14*(45), 33568-33586.

[63] Buchman, J. T., Hudson-Smith, N. V., Landy, K. M., & Haynes, C. L. (2019). Understanding nanoparticle toxicity mechanisms to inform redesign strategies to reduce environmental impact. *Accounts of chemical research*, *52*(6), 1632-1642.

[64] Sajid, M., Ilyas, M., Basheer, C., Tariq, M., Daud, M., Baig, N., & Shehzad, F. (2015). Impact of nanoparticles on human and environment: review of toxicity factors, exposures, control strategies, and future prospects. Environmental Science and Pollution Research, 22, 4122-4143.

[65] Imran, M., Jha, S. K., Hasan, N., Insaf, A., Shrestha, J., Shrestha, J., ... & Mohammed, Y. (2022). Overcoming multidrug resistance of antibiotics via nanodelivery systems. *Pharmaceutics*, *14*(3), 586.

[66] Choi, V., Rohn, J. L., Stoodley, P., Carugo, D., & Stride, E. (2023). Drug delivery strategies for antibiofilm therapy. *Nature Reviews Microbiology*, *21*(9), 555-572.

[67] Moradialvand, M., Asri, N., Jahdkaran, M., Beladi, M., & Houri, H. (2024). Advancements in nanoparticle-based strategies for enhanced antibacterial interventions. *Cell Biochemistry and Biophysics*, 1-20.

[68] Majumder, J., & Minko, T. (2021). Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery. *Expert opinion on drug delivery*, *18*(2), 205-227.

[69] Kyriakides, T. R., Raj, A., Tseng, T. H., Xiao, H., Nguyen, R., Mohammed, F. S., ... & Sheu, W. C. (2021). Biocompatibility of nanomaterials and their immunological properties. *Biomedical Materials*, *16*(4), 042005.

[70] Horie, M., & Tabei, Y. (2021). Role of oxidative stress in nanoparticles toxicity. *Free radical research*, *55*(4), 331-342.

[71] Mohammadpour, R., Dobrovolskaia, M. A., Cheney, D. L., Greish, K. F., & Ghandehari, H. (2019). Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications. *Advanced drug delivery reviews*, *144*, 112-132.

[72] Allahverdiyev, A. M., Abamor, E. S., Bagirova, M., & Rafailovich, M. (2011). Antimicrobial effects of TiO2 and Ag2O nanoparticles against drug-resistant bacteria and leishmania parasites. *Future microbiology*, *6*(8), 933-940.

[73] Huh, A. J., & Kwon, Y. J. (2011). "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. *Journal of controlled release*, *156*(2), 128-145.

[74] Hajipour, M. J., Fromm, K. M., Ashkarran, A. A., de Aberasturi, D. J., de Larramendi, I. R., Rojo, T., ... & Mahmoudi, M. (2012). Antibacterial properties of nanoparticles. *Trends in biotechnology*, *30*(10), 499-511.

[75] Skłodowski, K., Chmielewska-Deptuła, S. J., Piktel, E., Wolak, P., Wollny, T., & Bucki, R. (2023). Metallic nanosystems in the development of antimicrobial strategies with high antimicrobial activity and high biocompatibility. *International Journal of Molecular Sciences*, *24*(3), 2104.

[76] Bas, T. G. (2024). Bioactivity and bioavailability of carotenoids applied in human health: Technological advances and innovation. *International Journal of Molecular Sciences*, *25*(14), 7603.

[77] Santhosh, P. B., Genova, J., & Chamati, H. (2022). Green synthesis of gold nanoparticles: An eco-friendly approach. *Chemistry*, *4*(2), 345-369.

[78] Hejabi, F., Abbaszadeh, M. S., Taji, S., O'Neill, A., Farjadian, F., & Doroudian, M. (2022). Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems. *Frontiers in Chemistry*, *10*, 957572.

[79] Lei, L., Pan, W., Shou, X., Shao, Y., Ye, S., Zhang, J., ... & Shi, L. (2024). Nanomaterials-assisted gene editing and synthetic biology for optimizing the treatment of pulmonary diseases. *Journal of Nanobiotechnology*, *22*(1), 343.

[80] Tao, S., Chen, H., Li, N., & Liang, W. (2022). The application of the CRISPR-Cas system in antibiotic resistance. *Infection and drug resistance*, 4155-4168.

[81] Bikard, D., Euler, C. W., Jiang, W., Nussenzweig, P. M., Goldberg, G. W., Duportet, X., ... & Marraffini, L. A. (2014). Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. *Nature biotechnology*, *32*(11), 1146-1150.

[82] Yeh, T. K., Jean, S. S., Lee, Y. L., Lu, M. C., Ko, W. C., Lin, H. J., ... & Hsueh, P. R. (2022). Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy. *International journal of antimicrobial agents*, *59*(1), 106475.

[83] Sahoo, P. (2024). Complementary supramolecular drug associates in perfecting the multidrug therapy against multidrug resistant bacteria. *Frontiers in Immunology*, *15*, 1352483.

[84] Godoy-Gallardo, M., Eckhard, U., Delgado, L. M., de Roo Puente, Y. J., Hoyos-Nogués, M., Gil, F. J., & Perez, R. A. (2021). Antibacterial approaches in tissue engineering using metal ions and nanoparticles: From mechanisms to applications. *Bioactive Materials*, *6*(12), 4470-4490.

[85] Kretzmann, J. A., Evans, C. W., Moses, C., Sorolla, A., Kretzmann, A. L., Wang, E., ... & Blancafort, P. (2019). Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers. *Chemical Science*, *10*(33), 7718-7727.

[86] Singh, A. V., Rosenkranz, D., Ansari, M. H. D., Singh, R., Kanase, A., Singh, S. P., ... & Luch, A. (2020). Artificial intelligence and machine learning empower advanced biomedical material design to toxicity prediction. *Advanced Intelligent Systems*, *2*(12), 2000084.

[87] Bao, Z., Bufton, J., Hickman, R. J., Aspuru-Guzik, A., Bannigan, P., & Allen, C. (2023). Revolutionizing drug formulation development: the increasing impact of machine learning. *Advanced Drug Delivery Reviews*, 115108.

[88] Heydari, S., Masoumi, N., Esmaeeli, E., Ayyoubzadeh, S. M., Ghorbani-Bidkorpeh, F., & Ahmadi, M. (2024). Artificial intelligence in nanotechnology for treatment of diseases. *Journal of Drug Targeting*, *32*(10), 1247-1266.

[89] Olatunji, A. O., Olaboye, J. A., Maha, C. C., Kolawole, T. O., & Abdul, S. (2024). Revolutionizing infectious disease management in low-resource settings: The impact of rapid diagnostic technologies and portable devices. *International Journal of Applied Research in Social Sciences*, *6*(7), 1417-1432.

[90] Geng, H., Vilms Pedersen, S., Ma, Y., Haghighi, T., Dai, H., Howes, P. D., & Stevens, M. M. (2022). Noble metal nanoparticle biosensors: from fundamental studies toward point-of-care diagnostics. *Accounts of chemical research*, *55*(5), 593-604.

[91] Yetisen, A. K., Akram, M. S., & Lowe, C. R. (2013). based microfluidic point-of-care diagnostic devices. *Lab on a Chip*, *13*(12), 2210-2251.

[92] Kennedy, D. G., O'Mahony, A. M., Culligan, E. P., O'Driscoll, C. M., & Ryan, K. B. (2022). Strategies to mitigate and treat orthopaedic device-associated infections. *Antibiotics*, *11*(12), 1822.

[93] Abbas, J. J., Smith, B., Poluta, M., & Velazquez-Berumen, A. (2017). Improving health-care delivery in low-resource settings with nanotechnology: Challenges in multiple dimensions. *Nanobiomedicine*, *4*, 1849543517701158.

[94] Garza, D. R., & Dutilh, B. E. (2015). From cultured to uncultured genome sequences: metagenomics and modeling microbial ecosystems. *Cellular and Molecular Life Sciences*, *72*, 4287-4308.

[95] Thompson, T. P., & Gilmore, B. F. (2024). Exploring halophilic environments as a source of new antibiotics. *Critical Reviews in Microbiology*, *50*(3), 341-370.

[96] Sukhum, K. V., Diorio-Toth, L., & Dantas, G. (2019). Genomic and metagenomic approaches for predictive surveillance of emerging pathogens and antibiotic resistance. *Clinical Pharmacology & Therapeutics*, *106*(3), 512-524.

[97] Munk, P., Brinch, C., Møller, F. D., Petersen, T. N., Hendriksen, R. S., Seyfarth, A. M., ... & Aarestrup, F. M. (2022). Genomic analysis of sewage from 101 countries reveals global landscape of antimicrobial resistance. *Nature Communications*, *13*(1), 7251.

[98] Ding, M., Ye, Z., Liu, L., Wang, W., Chen, Q., Zhang, F., ... & Zhou, Y. (2022). Subinhibitory antibiotic concentrations promote the horizontal transfer of plasmid-borne resistance genes from Klebsiellae pneumoniae to Escherichia coli. *Frontiers in Microbiology*, *13*, 1017092.

[99] Torres-Cortés, G., Millán, V., Ramírez-Saad, H. C., Nisa-Martínez, R., Toro, N., & Martínez-Abarca, F. (2011). Characterization of novel antibiotic resistance genes identified by functional metagenomics on soil samples. *Environmental microbiology*, *13*(4), 1101-1114.

[100] Asante, J., & Osei Sekyere, J. (2019). Understanding antimicrobial discovery and resistance from a metagenomic and metatranscriptomic perspective: advances and applications. *Environmental microbiology reports*, *11*(2), 62-86.

[101] Santos-Pereira, C., Sousa, J., Silvério, S. C., Simões, M. F., Antunes, A., & Rodrigues, L. R. (2024). Metagenomics to unravel the microbial biodiversity and biotechnological potential of extreme high salinity environments. In *Functional Metagenomics* (pp. 77-130). Academic Press.

[102] Padhiary, M., Roy, D., & Dey, P. (2025). Mapping the Landscape of Biogenic Nanoparticles in Bioinformatics and Nanobiotechnology: AI-Driven Insights. In *Synthesizing and Characterizing Plant-Mediated Biocompatible Metal Nanoparticles* (pp. 337-376). IGI Global.

[103] Tawiah, B., Ofori, E. A., & George, S. C. (2024). Nanotechnology in societal development. In *Nanotechnology in Societal Development* (pp. 1-64). Singapore: Springer Nature Singapore.